[{"article": "Co-authors with Sharma, who presented the data at ASCO, are Petri Bono, Helsinki University Hospital, Helsinki, Finland; Joseph Kim, Yale Cancer Center; Pavlina Spiliopoulou, Beatson, West of Scotland Cancer Centre, Glasgow; Emiliano Calvo, Centro Integral Oncol\u00f3gico Clara Campal, Madrid,Spain; Rathi Pillai, Emory Winship Cancer Institute, Atlanta; Patrick Ott, Dana Farber Cancer Institute, Boston; Filippo DeBraud, Istituto Nazionale dei Tumori, Milan, Italy; Michael Morse, Duke University Medical Center, Durham, N.C.; Dung Le, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore; Dirk Jaeger, Heidelberg University Hospital, Heidelberg, Germany; Emily Chan, Vanderbilt University, Nashville, Tenn.; Chris Harbison, Chen-Sheng Lin, Marina Tschaika, Alex Azrilevich, of Bristol-Myers Squibb, and Jonathan Rosenberg of Memorial Sloan Kettering Cancer Center.\nLong-term follow up shows 22 percent of those treated with the drug survive 10 years or longer.\nTwo patients discontinued therapy because of adverse events related to the drug.\nIpilimumab was the first drug ever shown to extend the survival of patients with metastatic melanoma.\nInitial results from the Phase II portion of the trial will be presented later this year.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that the only drug currently approved \u201cfor second-line treatment of metastatic bladder cancer\u201d is a competing drug: atezolizumab. This would have been better if it had explained what \u201csecond-line treatment\u201d means \u2014 since many readers are not going to know.", "answer": 1}, {"article": "Rather, surgeons move electronic instruments that are linked to the movement of other instruments inside the body, while they watch a three-dimensional image of what\u2019s going on inside.\nThe robot-surgeon team might not have outperformed the surgeon alone because the procedure was a relatively simple one.\nIn this case, the robot could turn what would have to be an open surgery into a simpler one.\nThere was no difference in how much blood patients lost, and there were no complications in either group.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This was the entire point of the study and the point of the story. At least a mention of non-surgical treatments of endometriosis would have been nice, especially since the majority of cases can be treated nonsurgically. ", "answer": 0}, {"article": "\u2022 Retrograde menstrual flow: During a period, when a woman is shedding her uterine lining, some of that tissue can flow through her fallopian tubes and into her pelvis, which researchers think may cause endometriosis.\nWe have no idea about the long-term effects of taking the drug because there are no trials lasting for longer than a year, or how it stacks up against other painkillers (since the trials only compared it to placebo).\nSoon, it seems, women like Dunham with endometriosis pain will have a new option for relief.\nFor other women, though, the trade offs may be worth it.\nAn endometriosis pain treatment was just approved by the Food and Drug Administration, and it\u2019s expected to arrive at pharmacies as soon as August.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "A number of existing pain-reduction alternatives are mentioned, from hormonal treatments to surgery, and their debits discussed. It would have been helpful to try and articulate how many women find the current alternatives insufficient.", "answer": 1}, {"article": "Then at 9 to 10 weeks the mother's blood takes over to feed the embryo,\" said Kliman.\nBut for some women, every pregnancy results in a loss.\n\"They attached, but they were not getting enough food.\n\"This study has shown that the EFT can also be an important tool for patients with recurrent pregnancy loss,\" he said.\n\"The positive results show us that next we need to study progesterone as a treatment for recurrent pregnancy loss with a prospective randomized trial to validate the findings.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Are there alternative methods to determine the health of a fetus and other potential treatments to prevent miscarriage? The release doesn\u2019t say.", "answer": 0}, {"article": "Resveratrol is a naturally occurring compound found in foods such as red grapes, raspberries, dark chocolate and some red wines.\n\"Given safety and positive trends toward effectiveness in this phase 2 study, a larger phase 3 study is warranted to test whether resveratrol is effective for individuals with Alzheimer's -- or at risk for Alzheimer's,\" Turner says.\nA working hypothesis is that the treatments may reduce inflammation (or brain swelling) found with Alzheimer's.\n\"A decrease in Abeta40 is seen as dementia worsens and Alzheimer's disease progresses; still, we can't conclude from this study that the effects of resveratrol treatment are beneficial,\" Turner explains.\nWASHINGTON (Sept. 11, 2015) -- The largest nationwide clinical trial to study high-dose resveratrol long-term in people with mild to moderate Alzheimer's disease found that a biomarker that declines when the disease progresses was stabilized in people who took the purified form of resveratrol.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "It would have been helpful to know what standard treatments for Alzheimer\u2019s are and how resveratrol could compare with these drugs in the future. According to the National Institute on Aging, several other drugs on the market \u2013 like Donepezil (Aricept\u00ae), rivastigmine (Exelon\u00ae), and galantamine (Razadyne\u00ae) \u2013 may help slow down cognitive decline, but do not change the underlying disease process.\u00a0The release could have discussed the lack of great treatments, further supporting the importance of this work.", "answer": 0}, {"article": "Toxins produced by bacteria, such as salmonella, can severely harm the digestive system by damaging nerves critical to healthy gut function.\nFor more information on IBS and the new blood test for the disorder, watch this video:\n\nFirst Ever Blood Test for IBS\n\nCedars-Sinai has entered into an exclusive license agreement with Commonwealth Laboratories for several patent applications covering the blood tests, developed by Pimentel to detect both anti-CdtB and anti-vinculin antibodies in the diagnosis of irritable bowel syndrome and inflammatory bowel disease.\nThe tests, created by Mark Pimentel, MD, director of the GI Motility Program and Laboratory, confirm when a patient has developed IBS because of food poisoning, a major cause of the disorder.\n\"The fact that we can now confirm the disease through their blood, not their head, is going to end a lot of the emotional suffering I have seen these patients endure.\"\nNew blood tests will speed up diagnosis for the most common GI disorder\n\nLOS ANGELES (May 14, 2015) - Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release says that IBS has been \u201cnearly impossible to diagnose until now.\u201d But the release also says IBS \u201cis the most common gastroenterological disorder in the United States.\u201d There\u2019s a clear disconnect between these two statements. IBS may not be easy to diagnose, but it is diagnosed. Often, an IBS diagnosis is reached after other conditions have been ruled out. A diagnosis may also come after extensive additional testing. In other words, the new blood tests would be a significantly quicker and easier way to reach diagnosis. But the release should have simply said that.", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no discussion of alternate strategies for minimizing either the accumulation of arterial plaques specifically or heart disease generally.", "answer": 0}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Again, barely adequate in that the story at least discussed a bit about both DHA supplements and fish consumption \u2013 but wrapped this into broader healthy alternatives such as \"all pregnant women should strive for balance and eat a variety of foods, including fish.\"\u00a0\u00a0", "answer": 1}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\nWhile there has been greater success in treating cancer, survivors may live many years with side effects after treatment.\nWhile some risk factors are well-known -- including age, diabetes and poor cardiovascular health -- whether a man suffers harsh side-effects is often chalked up to random luck.\nKnowing a man\u2019s susceptibility to fallout from radiation may steer a doctor toward surgery instead of other potentially damaging therapy.\nFor men diagnosed with prostate cancer, the decision about how to treat it -- or even whether to treat it -- can be agonizing.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Alternative treatment approaches are not discussed. Presumably all subjects have cancer confined to the prostate and are eligible for attempted curative therapy (surgery or radiation). \u00a0However, a substantial proportion of early-stage cancers are low-risk\u2013and do not necessarily even require treatment. \u00a0These men face no risk for treatment-related erectile dysfunction. \u00a0The alternative active treatment\u2013surgery\u2013is actually much more likely than radiation therapy to cause erectile dysfunction. \u00a0The other major issue regarding treatment alternatives is whether patients would achieve better cancer control\u2013a potentially more important outcome for patients than the complication risks.", "answer": 0}, {"article": "After four weeks, when there tends to be some improvement in the placebo patients, 80 mg patients slept 7.7 percent more, while those who got the 40 mg dose slept 7.9 percent more.\nThe findings were presented at Associated Professional Sleep Societies meeting in San Antonio, Texas.\nOn average, it took patients 21.6 fewer minutes to fall asleep with the 40 mg dose of MK-4305 than a placebo on night one, Merck said.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\n\u201cWe are encouraged by these Phase II results showing positive effects of MK-4305 in patients with primary insomnia,\u201d Michelson said in a statement.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No. See comments above under \"novelty.\" Also, there is no sense in this story that drugs aren\u2019t the only solution to this problem. MayoClinic.com\u00a0 ticks through a number of alternatives to drug therapy, including \"Going to bed only when sleepy, Using the bedroom only for sleeping and sexual intimacy (as opposed to reading, writing, studying, watching TV, or other activities), Going to another room when unable to sleep and engaging in another activity until sleepy.\" You can find more here: http://www.mayoclinic.org/insomnia/treatment.html. ", "answer": 0}, {"article": "We know this.\nThe recommended dietary allowance works out to three or four servings each day of \"fortified\" foods such as milk, yogurt, soy beverages, orange juice or cereal, plus fatty fish twice a week, according to Manson's commentary.\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\n\"Large trials of other widely used supplements have sometimes found benefits,\" Manson wrote, \"but in other cases--such as with high doses of beta carotene, vitamin E and selenium--have disproven some health claims for these supplements and identified health risks that may not have otherwise been detected.\"\nShe also called on physicians not to overscreen patients for vitamin D deficiencies, a practice that can lead to overprescribing it.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story lays out what constitutes a healthy amount of vitamin D, how people can get that amount of vitamin D through their diet (or sunlight), and that some supplements may be needed.", "answer": 1}, {"article": "Sometimes, individuals with CDE have trouble opening their eyes, but Tomei said she went to the doctor and reported mild but incessant itchiness and dryness, and was diagnosed with CDE.\nIf you think you may be suffering from CDE, Tomei advised visiting your doctor to receive a diagnosis.\n\u201cIt was as simple as going to the doctor, getting a prescription and trying RESTASIS\u00ae,\u201d Tomei, 51, who stars in the upcoming \u201cSpider-Man: Homecoming\u201d movie, told FoxNews.com.\nOn Restasis.com, you can take the brand\u2019s \u201cdry eye quiz\u201d\u2014 for every quiz taken, Allergan has agreed to donate $1 to the organization.\nThe quiz on Restasis.com can help individuals learn whether they\u2019re a candidate for the drug.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article said that the actress Marisa Tomei \u201cturned to RESTASIS\u00ae because she didn\u2019t want to keep worrying about constantly using eye drops.\u201d So how does the product compare to\u00a0standard artificial tears?\u00a0Again, another lost opportunity to inform. With this drug, according to the product label, you still have to put it in your eyes at least twice a day.", "answer": 0}, {"article": "\"There is nothing new here at all,\" he said.\nThe medications, which include Requip (ropinirole), levodopa, Neurontin (gabapentin) and Lyrica (pregabalin), appear to reduce symptoms of the syndrome in more than 60 percent of patients, researchers report.\nWilt noted there is no information on the effectiveness of treatments in pregnant women, young or old patients, those with milder symptoms or those with other serious medical conditions.\nOne expert, Dr. Martin Niethammer, a neurologist at the Movement Disorders Center of North Shore-LIJ's Cushing Neuroscience Institute in Manhasset, N.Y., said this study is merely a review of the current treatments for restless legs syndrome.\nMONDAY, March 4, 2013 (HealthDay News) -- People suffering from restless legs syndrome may find some relief by taking one of several drugs approved to treat the condition, a new review confirms.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story notes that drugs may not be appropriate for individuals with milder symptoms, it didn\u2019t discuss what approaches might be useful.\u00a0Recommendations from the National Institute of Neurological Disorders include:\nThe key point is that for many individuals with mild symptoms, the cost, side effects and unclear longer term benefits and harms of these medications indicate that many patients will seek other options including options that are low risk but potentially of limited benefit.\n ", "answer": 0}, {"article": "All rights reserved.\nAlice Lichtenstein, a heart and nutrition specialist at Tufts University\u2019s Boston campus, said the results are encouraging but that other changes could have contributed, such as smoking bans and mandatory calories on menus.\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\nThe results translate to 43 fewer heart attacks and strokes per 100,000 people, said lead author Dr. Eric Brandt, a Yale University cardiology fellow.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned\u00a0smoking bans and mandatory calorie counts on menus, which could be considered alternative public health measures to reduce heart disease.", "answer": 1}, {"article": "Oral immunotherapy, swallowing small amounts of the allergen, has shown to be more effective than sublingual therapy, which involves putting even tinier quantities of milk under the person's tongue.\nResearchers are separately looking at a drug called omalizumab (Xolair), approved by the U.S. Food and Drug Administration for the treatment of severe asthma, to see if it could help people with food allergies, too.\nIt's still in the early stages, but Dr. Robert Wood of Johns Hopkins, who has been on the forefront of food allergy research, estimates the treatment could be brought to the public within six to eight years.\nThis is the first time the sublingual therapy has been studied in terms of its benefit as a precursor to the oral immunotherapy, Wood said.\nBut tree nuts may be harder to treat, Wood said, because tree-nut allergic individuals often have multiple kinds of nuts they can't eat.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story at least ended with mention of one other approach being studied:\nResearchers are separately looking at a drug called omalizumab\u00a0(Xolair), approved by the U.S. Food and Drug Administration for the treatment of severe asthma, to see if it could help people with food allergies, too.", "answer": 1}, {"article": "We think this test could change that,\" she said.\n\"We were looking at different types of brain lesions detected by the CT scans, ranging from mild to serious injuries, and found that the biomarker we tested for actually corresponded to the injuries.\nAs expected, the high definition imagery from the CT scans was able to identify which patients had suffered visible traumatic brain injuries.\nWhat makes them unique is that they pass the blood-brain barrier and enter the bloodstream, which makes them easy to detect with this particular test.\nMoreover, the study showed that the blood test detected symptoms of concussions, even when brain injuries were not visible on the CT scan.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The story provides information on the routine use of CT scanning as the standard for traumatic head injury. Since there are a host of biomarkers under study at the present time to detect concussion, we would have liked to have seen a couple of words on the other research taking place. \u00a0For example, Banyan Biomarkers has one additional biomarker under study at the present time.", "answer": 1}, {"article": "More than 25 million people in the United States and about 2.5 million Canadians suffer from chronic rhinosinusitis, or sinus infection, and experience compromised quality of life.\nThe study involved 871 patients from 72 primary care practices in England who were randomly assigned to 1 of 4 advice strategies: usual care, daily nasal and saline irrigation supported by a demonstration video, daily steam inhalation, or combined treatment with both interventions.\n\"Although there was no significant difference in either physician visits or antibiotic use, as might be expected over only a 6-month follow-up period, our findings concerning consultations are important in the longer term, given antibiotic use increases the risk of antimicrobial resistance.\"\nSince the impact was less than in previous studies that had used more intensive coaching about nasal irrigation, the authors suggest that further research is needed to understand how much coaching of patients is required.\nPatients who were instructed to use nasal irrigation showed improvement at 3 and 6 months, as measured by the Rhinosinusitis Disability Index.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release talks about alternatives for sinus infections ranging from doctor visits and potential prescriptions to at-home use of nasal irrigation or steam inhalation.", "answer": 1}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that anticoagulant medication is \u201cthe usual course of treatment for preventing clots.\u201d We\u2019ll rate the story Satisfactory on that basis, although\u00a0a broader discussion of established therapies for atrial fibrillation would have been welcome. As mentioned above, it simply isn\u2019t clear whether these devices are safer or more effective than treatments that have been shown to have favorable risk/benefit profiles in randomized studies.", "answer": 1}, {"article": "\"The ice ball forms very rapidly, \" Lee said.\nOnly one incision is required because Lee and other doctors can use a device called a trocar, which has holes for each instrument and the endoscope.\nBesides being tiny, Guiles said they offer the advantage of flexibility.\nHe also knew that the cancer happened to be a spot where the small instruments couldn't reach it, the operation might have to be much more extensive.\nThe hook, grasper and scissors are on the ends of shafts less than one-fifth of an inch wide.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentions open surgery, it does nothing to describe the pros and cons of the options.", "answer": 0}, {"article": "\"Nothing happens,\" he told Stahl.\nApril 2008: The Kanzius Machine\n\nMD Cancer Center: Have questions about cancer?\n60 Minutes decided to keep track of Kanzius and his invention, so we followed him for over a year, as he pushed to speed up the research on his machine and fought to slow down his own cancer, which was killing him.\nSo he wondered: if he injected a cancerous tumor with some kind of metal, would radio waves heat up the metal and cook the cancer cells to death, and only the cancer cells?\nWhat he did have was a deadly form of leukemia and a determination to use whatever time he had left to come up with a better way to treat the disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\n\n\n \nNot only does this story fail to discuss the range of treatment options available to patients with leukemia and other cancers, it broadcasts an egregious misrepresentation of the chemotherapy regimen given to John Kanzius by emphasizing the \u201chorrible side effects\u201d while failing to give standard treatment credit for Kanzius\u2019s temporary remission.\n The story also failed to mention that there are multitudes of experimental and proven cancer treatments that use targeted approaches that are conceptually similar to the Kanzius approach.", "answer": 0}, {"article": "RA Nash et al.\nOther studies have indicated that currently available MS drugs have lower success rates.\nNew clinical trial results provide evidence that high-dose immunosuppressive therapy followed by transplantation of a person's own blood-forming stem cells can induce sustained remission of relapsing-remitting multiple sclerosis (MS), an autoimmune disease in which the immune system attacks the central nervous system.\n\u201cThese encouraging results support the development of a large, randomized trial to directly compare HDIT/HCT to standard of care for this often-debilitating disease.\u201d\n\nMS symptoms vary widely and may include motor and speech difficulties, weakness, fatigue and chronic pain.\nThe most common form of MS is relapsing-remitting MS, which is characterized by periods of mild or no symptoms interspersed with symptom flare-ups or relapses.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release could have said more about other treatments beyond stating that other studies \u201chave indicated that currently available MS drugs have lower success rates,\u201d with no specifics.\nOne MS researcher told Medscape Medical News last year that current therapies yield a success rate of 38% to 48%. Thirteen medications have been approved by the U.S. Food and Drug Administration (FDA) for the treatment relapsing-remitting MS. All have been shown to reduce the number of attacks and new lesions, and they may also slow disease progression, according to the National Multiple Sclerosis Society.", "answer": 0}, {"article": "The page you are looking for has either moved or is not available (error 404).\n\nPlease return to the homepage or use the search box above to see if the page is available in a new location.\n\nIf you think this message is in error or need assistance, please email the webmaster.", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release notes that hydroxyurea is the only drug that has been approved by the Food and Drug Administration to treat sickle cell disease. We rate this Satisfactory since there are no other drug alternatives to name.", "answer": 1}, {"article": "Charli Scouller \n\nPR Manager (School of Medicine and Dentistry) \n\nQueen Mary University of London \n\nc.scouller@qmul.ac.uk \n\nTel: 020 7882 7943\n\nQueen Mary University of London (QMUL) is one of the UK's leading universities, and one of the largest institutions in the University of London, with 20,260 students from more than 150 countries.\n\"Gardasil 9 offers the potential to increase overall cervical cancer prevention from 70 to 90 per cent, nearly eliminating this cancer among vaccinated women.\nThe new vaccine, Gardasil 9, is not only safe but will offer greatly improved protection against cervical and other cancers.\nUntil late last year, there were two available vaccines to protect against HPV related disease (Cervarix and Gardasil).\nThe development of the new Gardasil 9 vaccine makes an important step in that direction.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does point out that there are two older vaccines that are available. It notes that\u00a0the quadrivalent vaccine protects against 4 strains of HPV, offering about 70 percent protection against cervical cancer, whereas the 9-valent vaccine protects against 9 strains and can prevent up to 90 percent of all cervical cancers. The release also mentions in passing that the vaccine can be discussed as part of a screening program in women ages 25 to 45. We feel that the release could have emphasized this more.", "answer": 1}, {"article": "The overall benefits were very small, with 26.5% of those randomly assigned to chelation experiencing a cardiovascular problem, compared with 30% of those randomly assigned to a placebo infusion.\nThat could lead to a bias in favor of chelation, Atwood says.\nYet some doctors say the study was far from rigorously performed, and so badly run that its marginally positive results are meaningless.\n\"The most exciting part of this study is that there may be an unexpected signal of benefit.\nNIH officials say the trial was worthwhile.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that there are\u00a0medications and\u00a0lifestyle changes that clearly have been shown to reduce heart disease. That\u2019s good enough.", "answer": 1}, {"article": "Suvorexant is part of a class of drugs called Dual Orexin Receptor Antagonists or DORAs, which work by blocking chemical messengers called orexins.\nSo far, Merck has not seen any cases of narcolepsy, a sleep disorder marked by daytime sleepiness, in its late-stage clinical trials, Renger said.\nExperiments in animals suggest Merck\u2019s sleep drug Suvorexant, now before the U.S. Food and Drug Administration, may avoid these side effects, the company said.\nOnly long-term use in large numbers of insomnia patients will reveal whether these drugs will be preferred to GABAergic hypnotics, and whether they produce rare complications, including narcolepsy-like symptoms in predisposed individuals,\u201d Mignot wrote.\n\u201cThese treatments work by forcing the brain to go to sleep,\u201d said study leader Jason Uslaner of Merck in an interview on the website of Science Translational Medicine, which published the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no mention of the many non-drug strategies for dealing with insomnia.", "answer": 0}, {"article": "\"Nicotine replacement therapies ... do not show any long-term effect on quitting even when combined with counseling,\" says researcher Gregory Connolly, DMD, director of the Center for Global Tobacco Control and professor of public health at the Harvard School of Public Health.\nThe findings are at odds with clinical trials, Connolly says.\nThe new study, however, draws from the population.\nBetter strategies are needed to prevent relapse, he tells WebMD.\nIt gives a more ''real world'' picture, he tells WebMD.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story gave a good, independent perspective about the fact that the preponderance of evidence is leaning toward a combination therapy of drugs and counseling.", "answer": 1}, {"article": "It is a miserable, frequent event that every physician knows about and many patients experience, but there is simply little available against it and nothing to prevent it.\u201d\nWasting syndrome is characterized by a loss of weight and muscle atrophy, and largely found in patients who suffer from cancer, kidney disease, chronic obstructive pulmonary disease, and heart failure.\nIn pre-clinical studies, compounds in thyme and oregano have demonstrated a greater than 37 percent increase in exercise tolerance and a 15 percent increase in muscle mass of certain body muscles.\n\u201cThis same calcium signal also activates signaling pathways to increase skeletal muscle endurance and also skeletal muscle size.\u201d\n\nSah\u2019s research team hypothesized that low level calcium cycling induced by these natural compounds might promote improved exercise capacity and overall metabolic health associated with healthy muscle mass.\nThe company plans to develop the discovery into an over-the-counter (OTC) product to combat cachexia.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The final paragraph of the release states that, \u201cThe treatment of cachexia just doesn\u2019t exist,\u201d but that\u2019s not the case. The medication megase is used in HIV related wasting and it\u2019s often offered to cancer patients as well. Some other interventions used to reduce the effects of cachexia include resistance exercise and a high-protein\u00a0diet. Psychological interventions are often used, as are other approaches which are aimed at both the cachexia and the underlying disease which causes it.", "answer": 0}, {"article": "St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children.\nShe said that the findings could have important applications for prevention, prognosis and treatment.\nThey also found that mice genetically altered to have reduced AIM2 function, when treated with the chemicals, showed significantly more tumors than normal mice.\nThey found that the mice showed drastically reduced AIM2 function, confirming the finding in humans with the cancer.\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not address any other treatments for colorectal cancer, nor does it mention screening or any of the steps that people can take to lower the risk of developing colorectal cancer \u2014 such as changes in diet or exercise. Since much of the release addresses the role of AIM2 in preventing cancer, this is problematic.", "answer": 0}, {"article": "The fibers within the tendons fray.\nIt had such a magical, immediate effect against pain.\nThe shots were quite effective, providing rapid relief of pain.\nThe pain relief could last for weeks.\nBut in terms of tennis elbow, the shots seemed to actually be counterproductive.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nThe article mentioned multiple treatment alternatives.\n", "answer": 1}, {"article": "Around the world, 21 million people have type 1 diabetes.\nGrowing islets will \u201csignificantly increase the number of patients who can receive the treatment,\u201d Keith Thompson, CGT\u2019s chief executive, told the World Stem Cells and Regenerative Medicine congress in London on Wednesday.\nThe pre-clinical results have encouraged CGT and Aberdeen University to create a spin-out company, called Islexa.\nInsulin shots could become a thing of the past for type 1 diabetes patients thanks to a technology being developed by Cell and Gene Therapy Catapult, a London-based not-for-profit organisation, and Aberdeen University.\nIf clinical trials are successful, the technology means tens of thousands more people could live without the need for frequent insulin injections, although it will take a few years until the treatment is available.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The\u00a0article mentions\u00a0current treatment with islet cell transplants as well as insulin shots, and that\u2019s enough to merit a Satisfactory rating. However, it doesn\u2019t mention\u00a0newer efforts to control type 1 with automatically programmed blood glucose monitor/insulin pumps and other means.", "answer": 1}, {"article": "Aneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening.\nCompared to other technologies, the stent graft can travel through smaller, curvy vessels and better adjust to a patient\u2019s anatomy.\nAfter my recovery, I know I will feel stronger and healthier, and will remain forever grateful.\u201d\n\nSince Angelino\u2019s surgery, Azizzadeh who, in conjunction with medical device company Medtronic, served as the national principal investigator in clinical tests of the device \u2013 has performed several additional, successful surgeries.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\n\u201cI feel very lucky to have benefited from this new and improved surgical technique and for the great doctors who cared for me.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that, \u201ccompared to other technologies, the stent graft can travel through smaller, curvy vessels and better adjust to a patient\u2019s anatomy.\u201d\nThe real question is: is that relevant? \u00a0Does this ability to travel through curvy vessels mean that the patients live longer and have fewer ruptures down the road?\nWe don\u2019t know and the news release didn\u2019t tell us.", "answer": 0}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses various dietary and lifestyle choices that can affect osteoporosis risk, which is great \u2014 and earns the story a \u201cSatisfactory\u201d rating here. However, there is one area where the story may have left readers a little confused. The story says \u201cother osteoporosis drugs have different trade-offs,\u201d but doesn\u2019t tell readers what that means. It also says, \u201cNewer osteoporosis drugs retailing for hundreds of dollars or more a month include Forteo (teriparatide) and Prolia (denosumab)\u201d \u2014 but then doesn\u2019t tell readers anything else about the drugs. If the drugs are worth mentioning, it\u2019s also worth explaining what they are, how they may be beneficial, or at least what some of those unnamed trade-offs might be.", "answer": 1}, {"article": "Micro-RNA are small non-coding RNA that control many genes and processes vital for cellular life such as metabolism, development and the immune system.\nCurrently, there is no definitive test for MS.\nThey are called miRNA because they are very short, only 18-25 letters long.\nPublished today in Scientific Reports, the discovery identifies tiny 'dysregulated' micro-RNA molecules that correctly diagnose MS and discriminate between patients at different disease stages - all in a simple blood test.\n\"This, in turn may lead to fewer relapses and a slower loss of brain volume, resulting in slowing or potentially halting progression of the disease for the person living with MS.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Several existing diagnostic elements are mentioned in the release; they are identified as \u201ccostly\u201d and as offering only limited help.\nWe\u2019ll rate this a marginal Satisfactory. More could have been said about the alternatives. What is the sensitivity/specificity and positive predictive value of these alternative tests? How do they compare as far as cost?", "answer": 1}, {"article": "Why smokers are more susceptible is not known for sure, but some scientists believe it has to do with smoking-caused damage that allows the bacteria to more easily attach to the lungs and windpipe, said Dr. Pekka Nuorti, a medical epidemiologist with the Centers for Disease Control and Prevention.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The original AP story discussed the inefficacy of the vaccine in younger people and mentions that there is no booster available, even though protection drops off after 5-10 years.\u00a0 But the NY Daily News deleted that section.\u00a0 The story does not mention how smoking cessation counseling will be administered with vaccine.\u00a0 The story also mentions deaths from pneumonia in those over 65, but we are not told how pneumonia is typically treated in this population and in younger people, or in smokers in particular.\u00a0 We don\u2019t know how many smokers need to be vaccinated to prevent one case of invasive infection; we don\u2019t know how many cases will be prevented by adopting this new strategy. This uncertainty is not made clear in this article.\u00a0 \n\u00a0", "answer": 0}, {"article": "Dr Francoise Soussaline, PhD, DSc, IMSTAR's president said: \"To bring a universal 'liquid biopsy' blood test for cancer to market, it must achieve a number of criteria, including high sensitivity and specificity and be fully automated with high throughput for a medical routine use.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\nThis is a generic test for cancer in an individual, regardless of the underlying mechanism that's causing their cancer.\nHowever, in their two most recent clinical trials of the test involving over 700 blood samples from colorectal and prostate cancer patients (and further breast and lung cancer samples that were available), they were unable to distinguish those with cancer from healthy patients in 60 cases.\n\"I'm now convinced that if we used the powerful IMSTAR system to look at thousands of cells on all the slide samples in the trials, we would see a significant increase in the overall predictability beyond the original 93 per cent of the original 2014 study.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release did attempt to explain alternatives. More could have been said about this, but we found it sufficient for a satisfactory rating:\nProfessor Anderson said: \u201cThis test is different from other universal cancer tests being developed, because it is not looking for a specific biomarker or mutation. This is a generic test for cancer in an individual, regardless of the underlying mechanism that\u2019s causing their cancer.\u201d", "answer": 1}, {"article": "March 31, 2010 -- A widely prescribed drug used to shrink enlarged prostates appears to reduce the incidence of prostate cancer in men with an increased risk for the disease.\nThe drugs work by blocking the conversion of testosterone into a key hormone associated with prostate growth.\nIn a trial involving more than 8,000 men from 42 countries, those who took the drug Avodart had a 23% lower risk of being diagnosed with prostate cancer over four years of treatment, compared to men who did not take the drug.\nWhile the studies suggest a role for Avodart and Proscar in the prevention of prostate cancer, experts tell WebMD that important questions remain about using the drugs for this purpose.\nStudy researcher Gerald L. Andriole, MD, says a significant proportion of men screened for prostate cancer fall into this clinically ambiguous category of having elevated PSAs and negative biopsies.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions finasteride as the primary alternative to Avodart for chemoprevention of prostate cancer.", "answer": 1}, {"article": "Moffitt is the No.\nThey also show that the vaccine was able to stimulate an immune response in the majority of the patients.\nThe researchers report that the dendritic cell vaccines were well-tolerated and patients only experienced low-grade toxicities.\nImportantly, the immune responses among the patients were similar, regardless of the route of vaccine administration.\nThe study was published in the December 13th online issue of Clinical Cancer Research and was supported by funds received from R01-CA096997, P30-CA016520, Pennies-in-Action\u00ae, and the Henle Foundation.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "This was a close call. The study was not looking at using the vaccine as an alternative to standard therapy; the research is too preliminary for that so we don\u2019t fault the release for its lack of a comparison with surgery/radiation. However, we\u2019re rating this Not Satisfactory for not noting that an alternative for early-stage cancers is no treatment or \u201cwatchful waiting.\u201d", "answer": 0}, {"article": "Because atrial fibrillation increases the risk for stroke, people with the condition are often prescribed blood thinners (also known as anticoagulants) to prevent blood clots that can cause a stroke.\nWhen the researchers focused on people who continued to take the drugs, they found an even larger reduction (48 percent) in the risk for dementia.\nDuring the study, more than 26,000 of the 440,000 participants, all with atrial fibrillation, were diagnosed with dementia.\n\"If you know that [atrial fibrillation] eats away your brain at a slow but steady pace and that you can prevent it by staying on treatment, I think most patients would find this a very strong argument for continuing treatment,\" he said.\nAlong with not taking blood thinners, the strongest predictors for dementia were age, Parkinson's disease and alcohol abuse, according to the study, published Oct. 25 in the European Heart Journal.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We learn that \u201calong with not taking blood thinners, the strongest predictors for dementia were age, Parkinson\u2019s disease and alcohol abuse.\u201d While this hints at some of the other factors that might influence dementia risk, it doesn\u2019t really get at strategies one might consider to actively stave off risk. The story could have mentioned some of these strategies including exercise and a healthful diet.\u00a0\u00a0", "answer": 0}, {"article": "\u2022 This is the first time tandospirone has be shown to reverse the deficit in brain neurogenesis induced by heavy alcohol consumption\n\u2022 The researchers also showed in mice that the drug was effective in stopping anxiety-like behaviours associated with alcohol withdrawal, and this was accompanied by a significant decrease in binge-like alcohol intake\n\n\"This is a novel discovery that tandospirone can reverse the deficit in neurogenesis caused by alcohol,\" said study leader neuroscientist Professor Selena Bartlett from QUT's Institute of Health and Biomedical Innovation.\nThe study by Professor Bartlett, Dr Belmer, Dr Patkar and Dr Vanessa Lanoue (Queensland Brain Institute) can be accessed here.\nQueensland University of Technology (QUT) researchers have identified a drug that could potentially help our brains reboot and reverse the damaging impacts of heavy alcohol consumption on regeneration of brain cells.\nThe findings have been published in Scientific Reports.\nProfessor Bartlett said researchers are constantly looking at new treatment strategies for alcohol abuse and addiction, which is characterised by extended periods of heavy alcohol use, binges and abstinence, and anxiety and depression which contribute to relapse.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no mention in the release as to alternative drugs that are used to treat heavy drinking, although there are some, or any mention of any non-drug approaches to curbing drinking.", "answer": 0}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted.\u201d\n\nThis study was presented at a medical conference.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n\u201cThis effect was largely consistent across study design with both case control and cohort studies showing a strong correlation,\u201d he says in a news release.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\u00a0There was no discussion of other factors that influence risk of colon cancer. It would require only a line in the story to do so. ", "answer": 0}, {"article": "Find her on Twitter at @maiasz.\nResponding to the research, Yale Child Study Center director Fred Volkmar told WebMD: \u201cThe question remains, \u2018Is fluoxetine better than risperidone for this symptom?\u2019 It would be interesting to see studies comparing these two drugs head to head.\u201d\n\nHollander has previously received funding from pharmaceutical companies, but the current study was paid for by a grant from the Food and Drug Administration\u2019s \u201corphan\u201d drug program.\nA previous, larger study of a similar medication, Celexa (citalopram), in autistic children did not find a reduction in repetitive behaviors, but the drug did reduce irritability and was superior to placebo among children who had the highest levels of irritability.\nPrior research on SSRIs in autistic people has also looked at Luvox (fluvoxamine) and found a reduction in repetitive behavior in adults but not children.\nWhen taking Prozac, Hollander says, \u201cPatients acknowledge experiencing less discomfort.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Here\u2019s where the story both excels and disappoints. It takes note of prior research on antidepressants and notes that the \u201conly drugs approved to treat irritability and repetitive behaviors in autistic children are the atypical antipsychotics Risperdal (risperidone) and Abilify (aripiprazole), which tend to have more severe side effects than Prozac does.\u201d What the story does not explain, though, is that Hollander himself has researched this exact topic and arrived at very similar conclusions, which may bolster his case in some ways and weaken it in others. In 2005, he found in the journal Neuropsychopharmacology that \u201cLiquid fluoxetine in low doses is more effective than placebo in the treatment of repetitive behaviors and that \u201cLimitations include small sample size\u201d.\nThere was also no mention of the possibility of behavioral treatments.\n\u00a0\n\u00a0", "answer": 1}, {"article": "\u201cHe and some of the other guys on the Nike team, it\u2019s well known they take advantage of the anti-gravity treadmill and the aqua track,\u201d Coates said.\nWalking on the underwater treadmill produced better measures when it came to maximal oxygen consumption (VO2max), a reflection of heart and lung function during exercise, and metabolic equivalents, a measure of energy use.\nAn alternative to a water treadmill: Some pool companies will install a water flow system you can work out against.\nSo, even older patients with limited mobility and balance don\u2019t have to negotiate getting down into a pool.\nFor those without access to a water treadmill, you can purchase a foam vest specifically designed for water jogging or use foam barbells to help keep you afloat.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The alternative to using a treadmill underwater would be to engage in cardiovascular exercise on dry land. The story addresses this, noting both the treadmill comparison study (mentioned above) and the fact that exercising in water reduces stress on joints. So, we\u2019ll give it a Satisfactory rating.\nHowever, the story intimates that exercising in a pool and exercising on an underwater treadmill are comparable. It\u2019s not clear that this is the case, and the 2014 story from Runner\u2019s World indicates that they are actually quite different. What\u2019s more, there is no discussion of another form of aquatic exercise: swimming. Is swimming a viable option for cardiovascular recovery?", "answer": 1}, {"article": "So, for example, a person who is actively using opioids and can't manage the withdrawals may be better suited for buprenorphine, while someone coming from a facility where he or she has detoxed and who doesn't want to use opioids may be better suited for naltrexone.\nWhat was important, Lee said, was for opioid addicts as well as treatment providers to understand that addiction isn't one-size-fits-all.\nWhat is key, said Dr. Miriam Komaromy, is meeting a patient where they are and understanding what best meets their needs.\nOnce on either of the medications, people fared equally well.\nAddiction \"is an incredibly deadly disease,\" said Komaromy, an addiction specialist at the University of New Mexico Health Sciences Center.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story compares two treatment drugs, as well as methadone. That\u2019s sufficient, although non-medication-assisted alternatives were not discussed.", "answer": 1}, {"article": ".\nOne U.S. neurologist agreed that the drug seems promising against a disease with few treatment options.\n\"A well-tolerated drug that produces even small benefits for patients with Huntington's disease would be a very welcome addition to the currently available treatments for this debilitating disorder,\" Andrew Feigin, from The Feinstein Institute for Medical Research in New York City, wrote in an accompanying commentary.\nMore than 70 percent of the patients taking the higher dose of the drug showed a significant benefit, according to the researchers.\nAccording to the study authors, this is the first drug shown to improve patients' loss of ability to move their muscles voluntarily.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article mentions tetrabenazine \u2013 the only drug on the market for Huntington\u2019s disease \u2013 and adds that it can \u201ccause serious side effects.\u201d", "answer": 1}, {"article": "Some patients experience grueling withdrawal if taken off opioids, while for others the symptoms are much less severe.\nBased on his reading of the data, \u201cit\u2019s John with PTSD on the 10 milligrams.\u201d\n\nBut as is true for addiction and pain treatments, adequate mental health care is also out of reach for many patients \u2014 showing just another way that the US health care system isn\u2019t built to adequately address the full needs of patients.\nBut the new study does offer a glimmer of hope in a fairly grim opioid epidemic: Maybe it is possible to reduce the amount of dangerous opioids that patients are consuming and still alleviate people\u2019s pain.\nSeveral of the studies were done in pain centers where they have expert programs, and those just are not widespread.\u201d\n\nIn fact, the lack of access to non-opioid strategies may be one big reason that doctors resorted to opioids in the first place.\nBut as Stanford pain specialist Sean Mackey emphasized to me, opioids should not be a first-line treatment due to the risks, and alternatives should be tried first.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This is one of the appreciable strengths of the story. It not only implies going cold-turkey as an option (and the pitfalls of that approach), but also digs into the topic of non-opioid pain-relief treatments to help patients deal with chronic pain as people they taper. We\u2019re also told how such\u00a0treatments\u00a0can be too expensive/out of reach for some, even those with health insurance \u2014 either due to lacking coverage or nearby access to capable doctors and facilities.", "answer": 1}, {"article": "Each person's genome, or complete set of DNA, is like a word that's the length of 3 billion characters; but spelled with only the letters A, T, C or G. Traditional DNA sequencing techniques decode sections of DNA 700 characters at a time, while NGS takes advantage of parallel computing capabilities, enabling scientists to decode millions of DNA fragments.\nIn the study, the research team profiled blood samples collected in a blinded study from children and adolescents 9-19 years to explore whether patients with spastic CP showed differences at the cellular level that routine orthopedic patients (needing ACL repairs, spinal fusions or other surgeries) did not.\nWhile the study findings indicate that there is a consistent signal present in circulating blood cells of children with spastic CP that remains from early childhood to the teenage years, the researchers say they need to further study samples from different age groups, including teenagers, toddlers, and infants from birth to 2 years.\nIf successful, the researchers say the type of blood test in development also may be useful for other disorders, such as infant leukemia.\nIn fact, there is no national surveillance here, but the CDC estimates that 1 in 323 American children have the condition.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions that currently, cerebral palsy patients are identified \u201cby monitoring motor milestones.\u201d\u00a0 It says also that there is currently no blood test available to identify CP patients younger that about two years old.", "answer": 1}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does mention that tears can be managed \u201cwithout surgery,\u201d but then it discredits this statistic by saying \u201cone\u2019s strength tends not to improve\u201d without surgery. It does not attribute that assessment, and readers may be left in confusion. Existing traditional surgery methods and non-surgical alternatives are not given the same weight in the story as new techniques. The Annals journal article referenced in the story stated: \u201cFuture studies of high quality are needed to explore the relative effectiveness of early vs. delayed surgery, nonoperative versus operative treatments.\u201d", "answer": 0}, {"article": "Boston, MA - Women who eat more high-fiber foods during adolescence and young adulthood--especially lots of fruits and vegetables--may have significantly lower breast cancer risk than those who eat less dietary fiber when young, according to a new large-scale study led by researchers at Harvard T.H.\nThe study will be published online February 1, 2016 in Pediatrics.\n\"This work on the role of nutrition in early life and breast cancer incidence suggests one of the very few potentially modifiable risk factors for premenopausal breast cancer.\"\nThe authors speculated that eating more fiber-rich foods may lessen breast cancer risk partly by helping to reduce high estrogen levels in the blood, which are strongly linked with breast cancer development.\nAs a community of leading scientists, educators, and students, we work together to take innovative ideas from the laboratory to people's lives--not only making scientific breakthroughs, but also working to change individual behaviors, public policies, and health care practices.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t discuss other risk factors for breast cancer at all, much less other lifestyle choices that can reduce risk, such as maintaining a healthy weight, exercising, limiting alcohol consumption or getting enough sleep. Perspective is needed about ways we can stay healthy overall and reduce later cancer risk.", "answer": 0}, {"article": ".\nThis study expands on the researchers' previous finding that dTMS reduced food cravings and induced weight loss in obese individuals.\nAfter five weeks of treatment, subjects receiving dTMS lost more than 3 percent of their body weight and more than 4 percent of their fat--significantly more than controls did, Luzi reported.\nCurrently approved in the U.S. for treating major depression, dTMS is being studied in some countries for the treatment of other neuropsychiatric disorders, especially addiction.\nUnlike deep brain stimulation, dTMS does not need an operation or implantation of electrodes.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While many strategies for weight loss are well known to the general public, none are mentioned in this release. It would be beneficial for readers to be able to compare the weight loss and metabolic changes in subjects who underwent dTMS to the results typically seen through changes in diet and physical activity, FDA-approved weight loss medications, or bariatric surgery, all of which are widely accepted treatments for obesity.", "answer": 0}, {"article": "\"The earlier we get treatment started, the better.\nIn cases where a diagnosis isn't necessarily clear-cut, the DaTscan offers important advances in patient care and treatment, said Dr. Michael Rezak, director of the Movement Disorders Center at Central DuPage Hospital, where the scan is offered.\nAs part of the study, recently diagnosed Parkinson's patients and healthy subjects are tested with DaTscan, and clinical and behavioral assessments are done to identify biomarkers of Parkinson's disease progression.\nApproval of DaTscan followed two Phase 3 clinical trials in which 284 adult patients with tremors were studied.\nA new scan to help in difficult-to-diagnose cases of Parkinson's disease or other parkinsonian syndromes is available at more than 80 U.S. hospitals, including some in the Chicago area, since receiving federal approval earlier this year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In the overwhelming majority of cases, a diagnosis of Parkinson\u2019s disease is made through clinical examination of the patient, including the specific pattern of tremors and other movement difficulties, followed by a test of drugs to see if they help ease the symptoms. The story not only fails to accurately describe conventional clinical tests and examinations used to establish a Parkinson\u2019s disease diagnosis, it misreports the primary purpose of the DaTscan test. ", "answer": 0}, {"article": "Age-related macular degeneration, or AMD, is the leading cause of vision loss among seniors, gradually eroding crucial central vision.\n\u201cFrom the basic science perspective, it makes a lot of sense.\u201d Macular degeneration tends to occur after age 60, but it sometimes strikes earlier.\nWhile the study is too small to prove if lampalizumab really helps maintain vision, that\u2019s a bigger difference than the overall results suggested.\nWASHINGTON\u2014An experimental drug is showing promise against an untreatable eye disease that blinds older adults \u2014 and intriguingly, it seems to work in patients who carry a particular gene flaw that fuels the damage to their vision.\nSymptoms often aren\u2019t noticeable early on.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are currently no approved or effective treatments for the geographic atrophy type of advanced macular degeneration, so there are no known alternatives with which to compare. The story makes this clear.", "answer": 1}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nRelated: Why Young Women are Having Heart Attacks\n\nThe team studied more than 450 people having heart bypass surgery, removing some of the fat clogging their arteries.\nIf the method holds up, doctors could start patients on drugs such as statins far earlier than they do now \u2014 in time to save them from ever developing serious heart disease, the researchers report in the journal Science Translational Medicine.\nResearchers say they\u2019ve developed a better way of scanning someone\u2019s heart to predict who is most at risk of a heart attack or stroke \u2014 long before conventional imaging methods can do it.\n\u201cTreatments that are known to reduce the risk of heart attacks, such as statin drugs, reduce inflammation much more than any detectable reduction in coronary artery narrowing,\u201d said Oxford\u2019s Keith Channon, who also worked on the study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does describe current means of assessing heart attack risk, as well as some interventions (surgical and medical) to address those risks.\nHowever, the article doesn\u2019t mention how this new technique would stack up against standard\u00a0tests\u00a0like stress tests or nuclear perfusion scans. There also is the option of simply treating people with risk factors and not utilizing imaging tests.", "answer": 0}, {"article": "To see if healthy tissue surrounding the cavity could be coaxed into healing the stroke injury, Segura engineered a gel to inject into the stroke cavity that thickens to mimic the properties of brain tissue, creating a scaffolding for new growth.\nIn addition to Carmichael and Segura, other authors of the paper are Lina Nih and Shiva Gojgini, both of UCLA.\nThe study was supported by funds from the National Institutes of Health.\nThe results suggest that such an approach may someday be a new therapy for stroke in people, said Dr. Tatiana Segura, a former Professor of Chemical and Biomolecular Engineering at UCLA who is now a professor at Duke University.\nThe mice with new neurons showed improved motor behavior, though the exact mechanism wasn't clear.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t discuss any of the current treatments available to patients injured by stroke. Nor does it mention any other related techniques currently under investigation.", "answer": 0}, {"article": "The U.S. National Institute of Allergy and Infectious Diseases has more on sinusitis.\nNone of which is to say that patients shouldn't try medical therapies first, he added.\nPatients with worse disease at the outset seemed to fare the best after the procedure, as did those undergoing surgery for the first time.\nThis second finding is probably explained by the fact that people going for second or further surgeries were probably sicker to begin with, Josephson said.\nFollowing the surgery, about 76 percent of patients had \"clinically significant\" improvement in quality of life, as measured by various validated scales.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentions that medical therapy can be an effective alternative to surgery, more information on the specific medications, including nasal steroids, oral decongestants and antihistamines,\u00a0would have helped readers. ", "answer": 1}, {"article": "Previous U.S. studies found that people with autism who received the hormone intravenously were less likely to engage in repetitive behavior that is another hallmark of autism and were more likely to be able to identify emotions in voices.\nThe hormone also heightens social sensitivity, social awareness, generosity and trust in people.\nAdministering the hormone soon after a child's autism is diagnosed might help him or her develop more normally, she said.\nIt plays a key role in social interaction, promoting maternal behavior and monogamy in animals.\nThe number of children found to have autism has been increasing for reasons that remain mysterious.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "", "answer": 0}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not provide a clear comparison between this drug and existing therapies. Olamizumab (Xolair), for example, has been available for a number of years to treat severe allergy and asthma.\u00a0 The story does note, helpfully, that the \u201cIn the first few weeks of the trial, when patients were still taking their existing drugs, there was no significant difference in the number of worsenings of asthma between dupilumab and the placebo\u201d.", "answer": 0}, {"article": "\"We compare the colored glasses to being like a brace or cast but for the brain,\" he says.\nIn addition to trying colored-lens sunglasses, the article suggests other ways to mitigate photophobia including wearing a wide-brimmed hat when outdoors, adjusting digital screen and device settings to an appropriate hue and brightness or purchasing filters for screens.\n\"While sunglasses can provide some relief, they are not very practical indoors or in low light environments,\" says Joe Clark, PhD, professor in the Department of Neurology and Rehabilitation Medicine at the UC College of Medicine and lead author of the study.\nHowever, the researchers noted, they do not recommend wearing colored glasses while driving.\nWe believe the use of the colored glasses that provide photophobia mitigation has added benefits superior to dark sunglasses, especially for indoor lighting.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions some alternatives for finding relief from photophobia:\n\u201cIn addition to trying colored-lens sunglasses, the article suggests other ways to mitigate photophobia including wearing a wide-brimmed hat when outdoors, adjusting digital screen and device settings to an appropriate hue and brightness or purchasing filters for screens.\u201d\nThe release also notes that people find some relief by wearing dark sunglasses.", "answer": 1}, {"article": "For ongoing (or chronic) pain \u2014 a sore lower back, say, or the kind of degenerative arthritis that typically develops with age \u2014 ibuprofen still outperforms acetaminophen.\nEither the outcomes in studies are badly defined, the studies have too few participants to say anything concrete, or many people in the studies actually seem to have chronic headaches as opposed to the ordinary ones the researchers are allegedly studying.\nSo I was surprised when I found out there's a huge gap between how pain researchers think about this drug and how the public does.\nIt turns out this is another fascinating problem area for pain researchers.\nMore specifically, every researcher I contacted for this piece said some variation of what Andrew Moore, a pain researcher at Oxford University, told me: Tylenol doesn't actually work that well for pain.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The main premise of the story was comparing which pain medication was the best for different types of pain. The comparisons are covered in depth with perspectives from three sources.", "answer": 1}, {"article": "But not a whole lot.\nExactly how well zinc works is a matter of future research, and the one day estimate may well change, the researchers note.\nThe bottom line: After seven days of treatment, those taking the supplements had less than half the chance of still being sick.\n\u201cBut giving zinc over a long period of time for prevention should be done very carefully,\u201d she told Reuters Health.\nStill, with an infection that currently has no good treatment and leads to an estimated 275 million lost work days a year in the U.S., well, what a difference a day makes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story didn\u2019t compare zinc to alternatives, which is a shame. People take many different drugs, supplements and home remedies to fight colds. We wish that even a few words had been given to the evidence for those treatments as well.\u00a0We would have liked to have seen some comment on the best ways to protect yourself and your family from getting a cold besides zinc products. A few words about hand hygiene and keeping your hands away from your eyes, mouth and nose would have been helpful to the readers", "answer": 0}, {"article": "And for the test to be useful, \"you've got to find cancer that's going to otherwise be lethal, and not cancer that would otherwise be destined to do nothing,\" Prasad says.\nOf course, the ultimate goal of this test is to find cancer in people who haven't already been diagnosed.\nThat's been a huge problem with previous cancer screening tests, especially for prostate cancer and breast cancer, and has led to pointless and potentially dangerous treatments, he says.\nSo Nickolas Papadopoulos, a professor of oncology and pathology at the Johns Hopkins Sidney Kimmel Cancer Center, collaborated with many colleagues at the medical school to develop a new approach.\nAn effective screening test would hold lots of potential for cancer patients, Prasad says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This was a tough call, but ultimately we felt the story would have been stronger had it mentioned the performance of current screening methods for some of the cancer types, such as Cologuard for colon cancer. That said, we were glad the story included some of the pitfalls of screening for prostate and breast cancer, as well as the long struggle to develop more blood tests for cancer.", "answer": 0}, {"article": "When skin is exposed to sun, it makes vitamin D.\n\nStill, the doctor wanted to run a blood test to see if Rebecca Rosen had adequate vitamin D.\n\n\"So my wife said, 'Well, why do I need to have a vitamin D [test]?'\nNot so fast, other experts say.\nThe fact that the government is funding the study is an indicator that the idea has traction.\nAre We Overselling The Sunshine Vitamin?\nManson and her colleagues are launching such a trial.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned a variety of sources for obtaining vitamin D.\u00a0 ", "answer": 1}, {"article": "Doctors diagnose Alzheimer\u2019s by excluding other causes of memory loss, such as stroke, tumors and heavy drinking.\nBut biomarkers \u2014 proteins and imaging techniques \u2014 are helping to identify the disease much earlier.\nThey can also administer simple paper-and-pencil tests.\nThe study is the latest to show that measuring disease-related proteins in spinal fluid is useful in diagnosing Alzheimer\u2019s disease.\nAnd they may also help identify early signs of the disease in healthy people, the team reported in the Archives of Neurology.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis story does not mention that brain scans are also being tested for their ability to aid in the diagnosis of Alzheimer\u2019s Disease.", "answer": 0}, {"article": "That compares with a 15-point decline in patients who initially received placebo and switched to IVIG, says Norman Relkin, MD, of Cornell Weill College of Medicine in New York City.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nThe findings were presented at the American Academy of Neurology meeting.\nThe drug is called Gammagard.\nApril 14, 2010 (Toronto) -- A decades-old drug made from human plasma appears to slow the decline of mental skills in people with Alzheimer's disease, suggest results from a small preliminary study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no comparison between these results and other Alzheimer\u2019s research, except for the Mayo expert\u2019s reminder that \"In the past few years alone, several Alzheimer\u2019s drugs that made it to this stage failed to pan out in further testing.\"\u00a0 However, because of the importance of that reminder at the very end of the story, we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "The studies suggest that fewer physicians are recommending annual mammograms for women in their 40s, fewer patients in that age group are getting screened and that tumors found through routine mammography are more likely to be detected in early stages of cancer.\nMeanwhile, younger women may feel as though they don't have to get this screening.\nAlthough the task force concluded that the net benefit of mammography in the 40s is small, Hardesty said: \"If you're the one person we find your cancer, it's the world to you.\"\n\"There is a real, but rather modest benefit.\nThe task force did not say don't get mammograms, Moyer said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was a far more balanced discussion of harms and benefits in this story, although the use of personal opinion and recommendations, and the ending resulted in an imbalance in the piece.\u00a0 Excerpts that demonstrate this imbalance:\nWouldn\u2019t a more balanced way to end the piece \u2013 focusing on the shared decision-making element so important in this issue \u2013 have been to end with this:\nNonethless, all of this was in the piece, so we\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "Asked if he's suggesting that it's some kind of a rejuvenation drug that would turn a 70-year-old into a 35-year-old, Westphal tells Safer, \"That might be pretty hard to do.\nEveryone from plastic surgeons to your friendly snake oil salesman have been promising a ticket to eternal youth for some time, so the prospect of a prescription pill based on red wine that could trigger a longevity gene sounds too good to be true.\n\"If the promise holds true, I think this has the chance to change healthcare,\" Dr. Christoph Westphal tells\n\nDr. Westphal says we all may soon be taking a drug that just might beat the clock, a simple pill that could delay the inevitable.\nAnd yet scientists have actually known for years of one surefire of doing that: stay hungry.\nTo maintain their sterile environment, the 60 Minutes team had to suit up to visit them with Ricki Colman, the \"project leader.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions calorie restriction as the other way to prevent aging and mentions exercise. The story should have done more to discuss these options. Instead, it practically dismisses them as difficult and ineffective.\u00a0 Story excerpt:\u00a0 \"But if the scientists at Sirtris are on the right track, it could mean forget dieting, forget the sweaty business of working out \u2013 just pop a pill and you are in guilt-free couch potato paradise.\"", "answer": 0}, {"article": "Grocers shelves add new coconut-water products regularly.\nI was meeting with a cardiologist recently, and he said he doesn\u2019t advise (coconut oil) for any clients.\u201d\n\nThe fat issue is complicated by the types of fatty acids found in coconut, versus other saturated fats.\n\u201cIf you focus on coconut oil, you lose out on the fiber and you are focusing on a concentrated source of calories.\nEven so, Little, a coconut enthusiast, doesn\u2019t recommend loading up on coconut fats.\n\u201cA lot of rehydrating beverages have additives, whereas the coconut water \u2014 it\u2019s super clean.\u201d\n\nCoconut oil and milk, though, are receiving mixed reviews.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The only comparisons we saw in this story were between coconut oil and butter. That was one line in a box that ran with the story and not enough to provide any meaningful comparisons to existing alternatives. Overall, readers are not given the information they would need to make informed comparisons between coconut-based products and other foods and drinks.", "answer": 0}, {"article": "In 2012, the Food and Drug Administration updated labeling on statins to include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\nLimiting factors should be a patient's own preference about taking a daily pill, price and the risk of diabetes, they said.\nOne of the recommendations was that statins should be prescribed to anyone with a 7.5 percent risk or higher of developing heart disease over the next 10 years.\nBut even with those risks, it\u2019s worthwhile, Gaziano\u2019s team found.\nPatients and doctors alike complained that the new guidelines were confusing.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not address alternatives to statin treatment such as diet and exercise.", "answer": 0}, {"article": "\u2022 Prostate cancer mainly occurs in older men; about 6 in 10 cases are diagnosed in men aged 65 or older.\nThe researchers said the analysis in their study is better at forecasting how prostate cancer will advance compared to the current diagnostic tests being used for prostate cancer such as the prostate specific antigen test and the Gleason score.\nWhile the findings need further research, larger clinical trials could give better information on individualized treatment for each prostate cancer type.\nThese genes demonstrated the risk of the disease progression, which was more accurate than the currently used Gleason score test and PSA test.\nThis could lead to a better quality of life and more effective treatment based on which prostate cancer a man is diagnosed with.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states that genetic testing is more accurate in predicting prostate cancer progression than either the PSA or Gleason score, but doesn\u2019t tell us how much more or accurate or how outcomes may be improved other than a vague statement about targeting and individualized treatment.", "answer": 0}, {"article": "This can last for hours, weeks, or even months after the completion of treatments.\"\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\nAs a consequence, cancer patients suffer poor appetite, weight loss, depression, and diminished nutrition, all of which are detrimental to recovery.\nOver time, taste and smell abnormalities (TSA) can lead to a loss of appetite and anorexic behaviors, compromising patients' ability to recuperate from the disease.\nTheir most recent study builds on the previous body of work through the application of lactoferrin supplements in treating taste and smell abnormalities.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "It\u2019s rather misleading to claim \u201cuntil now, there have been no reliable therapies\u201d for TSA, because this study cannot establish lactoferrin as a \u201creliable therapy\u201d based on only 12 patients.\nMany approaches\u00a0have been tried to help cancer patients cope with altered taste/smell including: dietary changes, Zinc supplementation, and agents which increase saliva production, to name a few.", "answer": 0}, {"article": "In a month, I bodysurfed at the beach,\u201d says Ellsberg, who is 81 .\nSo when students leave and begin their practices, it\u2019s no longer foreign to them.\u201d\n\nHamilton, who has performed 1,100 anterior procedures and strongly supports the method, says that despite growing interest, \u201cit will take a generation of new surgeons\u201d before use of the anterior approach is widespread.\nIf they\u2019ve had the posterior procedure, even if they don\u2019t consciously feel weak, they tend to shift their weight onto one foot and teeter like [Charlie] Chaplin.\u201d\n\nGiven benefits such as these, why haven\u2019t more surgeons switched methods?\nHamilton says that \u201cduring this time, they\u2019re taught both approaches.\u201d But he adds that \u201csince 2009, of the 13 fellows he trained, 12 use the anterior procedure as their primary approach in their practices.\u201d\n\nHamilton says that \u201ca decade ago, very few residencies and fellowships taught the anterior approach.\nAnother obstacle to the widespread use of the newer approach is that if established surgeons want to switch, they face time and cost constraints.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does compare the two alternatives on several different fronts. But it always felt like an uneven playing field.\u00a0 The evidence wasn\u2019t quantified. And so the story may oversimplify the debate between anterior and posterior approaches. Less invasive posterior techniques have been developed and are employed by many surgeons. It would have been helpful for the story to have surgeons comment on the relative benefits perceived between the anterior approach and less invasive posterior techniques. It may not be just an anterior vs. posterior issue.", "answer": 0}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There is no specific comparison to other weight loss programs or other approaches that might be beneficial for weight loss.", "answer": 0}, {"article": "Ketamine is a dissociative anesthetic in use since 1970's.\nDENVER, March 17, 2016 /PRNewswire/ -- A new study gives depression sufferers much hope if only they can get their doctors to look at this study.\n\"The wealth of clinical experience from treating hundreds of patients with ketamine has supplanted the preliminary data that emerged from the initial open-label and small double-blinded studies,\" said Dr. Henderson, who is a board certified psychiatrist, specializing in diagnosing and treating complex conditions, based in Denver, Colorado.\nCiting over 60 published scientific research studies, the new research article also reviews the molecular mechanisms by which ketamine invokes a robust activation of the brain's own repair mechanisms.\nIts findings stand in direct contrast to warnings from the American Psychiatric Association (APA).\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not tell us about the treatments that are approved for depression, nor does it say what percentage of people suffering from depression fail to find relief from them.", "answer": 0}, {"article": "May 17, 2012 -- An extract from the Chinese herb kudzu may help drinkers cut down on drinking, according to a new pilot study.\n\"They still drank, but they drank less.\"\nThe study is published in Drug and Alcohol Dependence.\nHe studied the extract puerarin.\nIt is one of the substances known as isoflavones found in kudzu.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that there are other medications approved for treating alcohol abuse and dependence, but they don\u2019t work for everyone. Some additional detail about these medications wouldn\u2019t have been out of place, but we\u2019ll call it good enough for a satisfactory.", "answer": 1}, {"article": "To make sure it works, though, the Centers for Disease Control and Prevention says doctors need to do a number of things:\n\u2022 Prescribe Truvada only for men at high risk of getting infected \u2013 that is, only for men who have sex with men, those who have multiple sex partners, and those who live in areas where there's a lot of HIV circulating.\nIt's the first time anybody's shown that taking a pill can prevent HIV \u2013 and it was the first new weapon against HIV unveiled in many years.\nAmong those whose tests showed they really did take it every day, the risk of HIV infection was 92 percent lower than those not on the drug.\nThe pill, called Truvada, is already on the market for treating HIV infections.\nBut the landmark study, involving 2,500 men who have sex with men, showed that taking Truvada faithfully can reduce the risk of infection by as much as 92 percent.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Not applicable.\u00a0 Because of the nature of this drug, no comparison is really necessary.\u00a0 As the story stated, \u201cIt\u2019s the first time anybody\u2019s shown that taking a pill can prevent HIV \u2013 and it was the first new weapon against HIV unveiled in many years.\u201d", "answer": 1}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentioned that the study demonstrated that there could be benefit from the treatment of elderly hip-fracture patients with this drug or another bisphosphonate.", "answer": 1}, {"article": "Bisphosphonates include such common drugs as Fosamax (alendronate), Boniva (ibandronate), Actonel (risedronate) and Reclast (zoledronic acid).\n\"In particular, all Americans, 50 or older, should get a screening test so that precancerous polyps can be detected and removed before they turn into cancer.\"\nFortunately, there are other proven ways to help lower risk of colorectal cancer, he said.\nHowever, these results should be interpreted with caution and require confirmation by additional studies, he said.\nA randomized trial is need to prove that bisphosphonates are protective against colorectal cancer, Rennert said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Both stories relied on Jacobs from the American Cancer Society for the same bit of context.\u00a0\u201cFortunately, there are other proven ways to help lower risk of colorectal\u00a0cancer, he said. \u201cIn particular, all Americans, 50 or older, should get a screening test so that precancerous polyps can be detected and removed before they turn into cancer.\u201d", "answer": 1}, {"article": "Parkinson's disease is a degenerative condition that affects the central nervous system.\nBut, he added, it's important for people to realize that this research isn't applicable to people who already have the disease.\n\"Berries could be a neuroprotective agent.\nHe also said it will be important to confirm these findings in other studies and learn the mechanism of how berries and other flavonoids appear to offer some protection against Parkinson's disease.\n\"For total flavonoids, the beneficial result was only in men.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There aren\u2019t really any effective alternatives for preventing Parkinson\u2019s disease, so we\u2019ll rule this not applicable.", "answer": 2}, {"article": "Toby's mother died of ovarian cancer when Toby was in her 20s.\nIt confirms what smaller studies have suggested in the past: Women who have a family history of breast cancer can greatly reduce their chances of getting the disease by having a double mastectomy.\nAnd, with ovarian cancer, the ovary leaves behind cells that could go on to become cancerous.\nPreventable because I can identify the fact that they had a higher risk of getting breast cancer,\" she says.\n\"We found mastectomy provided huge risk reduction of subsequent breast cancer diagnosis and death.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nAlthough the story mentions that women who have BRCA1/2 mutations may opt for intensive monitoring to catch disease early, it portrays that option as unreasonable. ", "answer": 0}, {"article": "Both VEGF Trap-Eye and Lucentis block a protein called vascular endothelial growth factor that causes blood vessels to grow and leak into the eye.\nRegeneron said the two drugs were equally safe.\nDr. Peter J. Francis, an associate professor at the Oregon Health and Science University, which will be a site for the trial, says the eye is a good place to test stem cell therapy because it is accessible.\nAlso, he said, there is less chance of rejection of the implanted cells because the eye is shielded somewhat from the body\u2019s immune system.\nStill, even starting the trial could be a boost to Advanced Cell, which often makes headlines but has struggled to raise money.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Laser surgery and photodynamic therapy are other potential treatment options for wet AMD. The story did not mention them.", "answer": 0}, {"article": "\"We were very intrigued by the higher lean mass, the possibility that vitamin D can help infants to not only grow healthy skeletons but also healthy amounts of muscle and less fat,\" said Hope Weiler, one of the study's authors and Director of the Mary Emily Clinical Nutrition Research Unit at McGill University.\nThe new study confirmed the importance for the development of strong bones of a vitamin D supplement of 400 IU/day during a baby's first year.\nThe only other factor found to make a significant difference to the children's amount of body fat was their level of physical activity.\nThis amount is in line with current Canadian health guidelines.\nBut the body scans used to assess bone density also allowed the team to measure the children's muscle and fat mass.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "We\u2019ll give the release a Satisfactory for noting that physical activity is another factor making \u201ca significant difference to the children\u2019s amount of body fat.\u201d The release would have been improved if it had noted that diet, home and family environment can affect the healthy development of young bodies.", "answer": 1}, {"article": "Visit http://www.\nA new study, 'Fresh Pear Consumption is Associated with Better Nutrient Intake, Diet Quality, and Weight Parameters in Adults: National Health and Nutrition Examination Survey 2001-2010,' published in Nutrition and Food Science, revealed new information regarding the health benefits of pear consumption.1 Of particular interest given the high rates of obesity in the United States, the study found that adult pear consumers had a lower body weight than non-pear consumers and they were 35 percent less likely to be obese.\nIn addition to discovering a correlation between fresh pear consumers and lower body weight, the study found that pear consumption was associated with higher diet quality (as defined by the Healthy Eating Index).\nMoreover, the consumption of one medium fresh pear per day had a positive effect on nutrient intake since consumers had higher usual intakes of dietary fiber, vitamin C, magnesium, copper, and potassium, and higher mean intakes of total sugars; consumers of fresh pears also had lower intakes of total, monounsaturated fatty acids, saturated fatty acids, and added sugars.\nThe epidemiologic study, led by Carol O'Neil of the Louisiana State University Agricultural Center, used a nationally representative analytic sample to examine the association of fresh pear consumption with nutrient intake, nutrient adequacy, diet quality, and cardiovascular risk factors in adults.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Like Macy\u2019s and Gimbel\u2019s, commercial competitiveness is unlikely to lead the Pear Bureau to carry water for, say, the Banana Bureau, or the Peach Bureau. But the release would have been strengthened by more explicitly noting the potential role of other high-fiber fruits and foods in a good diet.\nThere was no mention of other alternatives to weight loss on a dietary or any other level. This article almost makes it seem that pears are the greatest solution. But when we compare the 4 grams of dietary fiber in pears with other fruit we find that a large apple contains 4.5 grams and 3 dried figs have 10.5 grams.", "answer": 0}, {"article": "(That\u2019s a high dose; a 3 oz.\nportion of salmon contains anywhere from half a gram to 1g of omega-3.)\nCan omega-3 fat provide similar benefit?\nThese are questions Kwong and others hope to answer with more studies.\nMost of the people also started taking the supplements two to four weeks after their heart attack.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No alternatives to fish oil were discussed.", "answer": 0}, {"article": "In practice, Performance with Purpose means providing a wide range of foods and beverages, from treats to healthy eats; finding innovative ways to minimize our impact on the environment and reduce our operating costs; providing a safe and inclusive workplace for our employees globally; and respecting, supporting and investing in the local communities where we operate.\nNewly published research in the Journal of the American College of Nutrition showed that a hearty bowl of instant oatmeal helped curb food intake at lunch better than a leading oat-based, cold cereal -- even when each bowl provided the same number of calories.\nAuthors stated that the processing of the cold cereal might lead to changes in the oat fiber that reduced its ability to enhance satiety.\n\"The satiety benefits of instant oatmeal alone were important findings,\" remarked lead author Candida Rebello, MS, RD, of Pennington Biomedical Research Center at Louisiana State University.\nThe statistically significant results of the randomized, controlled crossover study (n=47) showed that a 250-calorie instant oatmeal serving (with an additional 113 calories of skim milk) enhanced satiety and feelings of fullness, reduced the desire to eat and may even lead to a lower caloric intake at lunch, compared to a 250-calorie serving of cold, oat-based cereal, also served with an additional 113 calories of skim milk.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study is ostensibly a head-to-head comparison of instant oatmeal and cold cereal. But there is no context provided in the release as to whether the purported benefits of oatmeal for breakfast are any better than other foods, including even other brands of the same types of foods. There has been a lot of research into the role of fiber-containing foods in controlling hunger and promoting weight loss \u2014 but the release doesn\u2019t get into any of that research.", "answer": 0}, {"article": "Flu season has already begun, and last year\u2019s was one of the most lethal in decades; about 80,000 Americans died of flu or its consequences, the Centers for Disease Control and Prevention said earlier this month .\nThe pill will cost $150, according to a spokeswoman for Genentech, which will sell Xofluza in this country.\nThe new antiviral, generically known as baloxavir marboxil but sold under the brand name Xofluza, is a single dose treatment.\nGenentech will offer coupons that lower the price to $30 for patients with health insurance and to about $90 for the uninsured.\nstill strongly recommends that every American over the age of six months get a flu shot as soon as possible.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story addresses the similarities (and differences) to other drugs that address flu symptoms, particularly oseltamivir (Tamiflu).", "answer": 1}, {"article": "When Downing expressed concerns about the drug, she said the doctor blew her off: \"He said, 'What are you worried about?\nDowning's family offers a powerful case study into the pros and cons of new guidelines recommending widespread screening of adolescents for mental disorders: Last month, the U.S. Preventive Services Task Force, a federal group that makes public health recommendations, said that all adolescents between ages 12 and 18 should be screened for major depression.\nBy contrast, she said, the multiple screenings that Caroline received carefully evaluated the child as an individual and homed in on the kind of therapy that was best for her.\nCandace's treatment, Downing said, involved a one-size-fits-all approach to mental health that sees medications as a magic pill.\nShortly after Candace's death, the Food and Drug Administration placed black-box warnings on several antidepressants to say they elevated suicidal thinking among some children.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story did not clearly delineate the treatment options for managing major depressive disorder in adolescents. \u00a0It should have indicated that serotonin re-uptake inhibitors, psychotherapy, and a combination of the two are all currently recommended for this age group. \u00a0Omitting combination treatment is especially problematic.", "answer": 0}, {"article": "Prostate cancer is the most common cancer among men.\nIn this study, after 12 months, it\u2019s a 9-in-10 chance.\u201d\n\nThe men in the study were aged 45 to 80 with medium- to high-risk cancer, and would likely have undergone surgery or radiotherapy down the line.\n\u201cFocal therapy of individual prostate-cancer lesions, regardless of whether they are multifocal or unifocal, leads to a low rate of genitourinary side-effects and an encouraging rate of early freedom from clinically significant prostate cancer,\u201d the authors concluded in the study.\nOverall, about 95% of the men were cancer-free after a full year following the trial.\nWhile the initial results were promising, they need to be replicated; HIFU also needs to be studied long-term and compared with other therapies.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "As noted in the \u201cEvidence\u201d criterion above, we feel the story allowed the researcher to get away with making comparative claims of superiority after a very preliminary study in just 41 men.\nAmong the other therapies to be mentioned would be active surveillance (deferring any active treatment until/unless there is evidence of cancer progression), which is an appropriate strategy for men with low-risk cancers (27% of the study group according to the Lancet article).\n\u00a0", "answer": 0}, {"article": "Drugs such as aspirin and ibuprofen treat inflammation, the body's immune response to infections or pathogens.\n\"We need more studies,\" he said, particularly research involving patients with depression who are inflamed but healthy to investigate the effect of these drugs on depression.\nSome are so new, clinical trials are still testing their efficacy and safety for human use.\n(CNN) In the future, a new class of anti-inflammatory drugs could be used to treat depression, say University of Cambridge researchers.\nKhandaker said that five of the 20 studies focused on one specific cytokine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story makes an oblique and somewhat misleading reference to research suggesting anti-cytokines are better than \u201cantipsychotic\u201d medicines, but no reference at all to types and use of antidepressants, many of which are effective.", "answer": 0}, {"article": "They also lost weight,\" Dandona tells WebMD.\nAnd during Victoza treatment, patients needed less and less insulin.\nAdding Victoza to insulin therapy quickly eliminated these peaks and dips in blood sugar.\nPatients who continued treatment for 24 weeks had further decreases in insulin doses, and lost an average of 10 pounds.\nThis appeared to be due to reduced appetite and food intake.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that another drug in the same class as Victoza might have similar benefits in type 1 diabetes. The\u00a0story\u00a0might have included more information\u00a0about the importance of testing blood sugars, frequent insulin changes, and careful dietary monitoring in improving control of diabetes.", "answer": 1}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Well, the story does mention that an alternative to Botox, a product called Reloxin, may be approved by the FDA soon. \nThe story implies that getting no treatment for wrinkles is a reasonable alternative.\u00a0 \nIt would have been useful, however, to hear about other cosmetic treatments\u2013fillers, laser treatments, creams, and so on\u2013that are used on wrinkles, whether they are shown to \"work\" or not.\u00a0 ", "answer": 1}, {"article": "Some doctors are raising concerns about a new cancer-treatment device that uses electrical jolts to zap tumors but that hasn't been through a large clinical trial to prove it's safe and effective in people.\n\nThe device, called NanoKnife, is currently being used in about 13 U.S. hospitals including Baptist Health Medical Center in Little Rock, Ark., University of Louisville, and Shands Hospital/University of Florida in Gainesville, Fla. Each machine costs as much as $300,000. Some of the hospitals are aggressively promoting...", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not do a very good job of contrasting this treatment with other treatments. This is disappointing because one of the claims made by the manufacturer\u2019s CEO is: \"We think this is a very promising technology for treating cancer that is otherwise untreatable.\" Some specifics about those cancers and how they are otherwise treated would have been nice. Because the NanoKnife has not been compared to a more traditional surgical approach, the benefits of the new technology are hard to\u00a0define. Unfortunately the story relies on a biased statement by the CEO of the manufacturer as its sole comparator.", "answer": 0}, {"article": "And I am completely pain free.\"\nJoint-replacement patients these days are younger and more active than ever before.\nPersonal quality of life issues are also important in deciding whether\u2014and when\u2014a patient is ready for joint-replacement surgery.\nSeveral studies of hips and knees implanted in patients long ago have found that 85% to 90% are still functioning well after 20 years.\nMost orthopedic surgeons encourage patients with hip and knee implants to walk, swim and cycle as much as possible.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "\nThe article did not discuss potential alternative treatments. This is a key question, since joint replacement has not traditionally been employed in this age group. Alternative therapies might include weight loss and other lifestyle interventions, exercise programs, activity modification, various medications, and other forms of surgery.\nThis is where the article could have been much tougher. Are these younger individuals exchanging short-term benefits for long-term problems with failed joint replacements? Some tough questioning of the patients would have been interesting. Were they even aware that they had other treatment options? Many individuals employ lifestyle changes and exercise to cope with knee problems for many years\u2014and preserve a reasonable quality of life. They might not experience the level of athletic performance demanded by the patients in this article. But in delaying joint replacement they may have better long-term treatment results.", "answer": 0}, {"article": "\"I've been through it, it was the past, time to move on,\" he said.\nBut seven years ago, his parents were concerned by an unusual number of bumps on his head, reports CBS News correspondent Dr. Jon LaPook.\nAfter two years, 46 percent receiving standard treatment alone were free of tumor recurrence versus 66 percent of those like Brian who also received the antibody.\nAfter several trips to the doctor, the Mullins received the worst possible news.\nIn results released Thursday, immunotherapy improved the outcomes of patients with advanced neuroblastoma.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story offered a list of treatments that the featured youngster had undergone. \u00a0While mentioning that the study results discussed came from a clinical trial, there was no discussion about whether there were other modalities currently under investigation for treatment or management of neuroblastoma.\u00a0 ", "answer": 0}, {"article": "During transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nAnd according to the new study, it helps.\nDec. 14, 2011 -- It can be an all too common scenario for certain stroke survivors.\nThis is often not enough to make a meaningful improvement.\nThere were no improvements seen in test scores of those who got the other treatment.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story says that \u201cneglect\u201d symptoms after stroke are usually treated with\u00a0cognitive and physical therapy,\u00a0but that this is \u201coften not enough to make a meaningful improvement.\u201d Later, however, it quotes an expert who says that this kind of rehab alone \u201ccould and should be enough to treat this kind of stroke.\u201d Well, which one is it? We\u2019ll give the story credit for addressing this criterion, but wish there had been a bit more clarity on the effectiveness of standard rehab.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThese findings indicate that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.\nThe Brain Trauma Indicator was reviewed under the FDA\u2019s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.\n\u201cThe FDA\u2019s review team worked closely with the test developer and the U.S. Department of Defense to expedite a blood test for the evaluation of mTBI that can be used both in the continental U.S. as well as foreign U.S. laboratories that service the American military.\u201d\n\nThe Brain Trauma Indicator works by measuring levels of proteins, known as UCH-L1 and GFAP, that are released from the brain into blood and measured within 12 hours of head injury.\nThe FDA reviewed and authorized for marketing the Banyan Brain Trauma Indicator in fewer than 6 months as part of its Breakthrough Devices Program.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release explains very well the typical ways that a brain injury is evaluated in an emergency department. It compares these blood tests with the existing standard, a CT scan.", "answer": 1}, {"article": "The Food and Drug Administration does not endorse DHA or fish oil capsules, but recognizes doses of up to 3 grams a day of fish oil as generally safe.\nDr. Ernst J. Schaefer, the lead author of the study, was cautious in interpreting the results.\n\u201cIt\u2019s an observational study that presents an identified risk factor, and the next step is a randomized placebo-controlled study in people who do not yet have dementia.\u201d Dr. Schaefer is chief of the Lipid Metabolism Laboratory at Tufts University.\nThe study was financed in part by Martek, a concern that manufactures DHA, and one author received a grant from Pfizer, France.\nDr. Schaefer pointed out that the kind of fish consumed is important.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story did not mention the lack of evidence-based measures to prevent Alzheimer disease.\u00a0 A brief statement about lack of strong evidence would help guide readers in this regard.", "answer": 0}, {"article": "LONDON (Reuters) - British scientists conducting early-stage research have found that a potential new drug from GlaxoSmithKline could treat mixed-lineage leukemia(MLL) \u2014 the most common form of leukemia in babies.\nIn a study published in the journal Nature, scientists from the British drugmaker collaborating with the charity Cancer Research UK (CRUK) and Cellzome AG found that the experimental drug, called I-BET151, mimics a chemical tag which is key to preventing the process of activating the leukemia genes.\nMost patients don\u2019t respond well to standard leukemia treatments and often the cancer comes back.\n\u201cThis ... is an exciting new avenue for drug discovery which we hope will be useful for other types of cancer in addition to MLL-leukaemias,\u201d said Tony Kouzarides of the Wellcome Trust/CRUK Gurdon Institute at Cambridge University, who co-led the study.\n\u201cWe urgently need better ways to treat children with more aggressive forms of leukemia, such as MLL,\u201d said Lesley Walker, CRUK\u2019s director of information.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There is no meaningful comparison between this experimental approach and other research or treatment approaches \u2013 only a statement that \u201cmost patients don\u2019t respond well to standard leukemia treatments and often the cancer comes back.\u201d", "answer": 0}, {"article": "\"This simple technology can be owned, operated, and distributed by Africans for Africans,\" Weathers said.\nThe 18 patients, ranging in age from 14 months to 60 years, did not respond to the standard ACT treatment, and all lapsed into severe malaria, defined by symptoms that can include loss of consciousness, respiratory distress, convulsions, and pulmonary edema.\nThe report documents the experiences of 18 patients in the North Kivu province of the Democratic Republic of Congo who showed symptoms of malaria and were originally treated with the recommended medication: artemisinin-based combination therapy (ACT), which blends artemisinin, a chemical extract from Artemisia annua, with one or more other drugs that attack the malaria parasite in different ways.\n\"Successful treatment of all 18 ACT-resistant cases suggests that DLA should be rapidly incorporated into the antimalarial regimen for Africa,\" they added, \"and possibly wherever else ACT resistance has emerged.\"\n(Weathers noted more than 100 other drug-resistant patients also have been successfully treated with DLA tablets.)\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release states all patients had previously received artemisinin-based combination therapy (ACT), followed by intravenously administered artesunate, a medication for severe malaria, but did not respond to either.\nThe study is perhaps different than most because these patients had exhausted other therapies available to them and received this new therapy under experimental \u201ccompassionate use\u201d rules.", "answer": 1}, {"article": "Surgery is considered by some to be the most definitive treatment, and there is evidence from other studies that it has better long-term cancer outcomes than radiation for higher-risk cancers, but it has more sexual and urinary side effects than radiation.\n- None of the treatments had an impact on general quality of life, such as the ability to do activities of daily living, emotional health and energy or vitality.\nThree-year survival from prostate cancer was excellent in the study at over 99 percent for patients regardless of whether they chose surgery, radiation or active surveillance.\nResearch reported in this article was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) award CE12-11-4667.\n\u201cUrinary incontinence was reported as a moderate or big problem in 14 percent of men three years after surgery compared to 5 percent of men who had radiation,\u201d Barocas said.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study was about comparison of alternatives and the release did a good job explaining what the alternatives were \u2014 surgery, radiation and active surveillance.", "answer": 1}, {"article": "One group of researchers, for example, recently worked backward to take on the problematic overlap between depression and bipolar disorder\u2014many bipolar patients are initially and incorrectly diagnosed with depression.\nDespite these exciting preliminary findings, there aren\u2019t yet any biological tests for mental illness widely used in medical practice.\nThe problem is that mental health diagnosis has essentially remained unchanged for 100 years, relying on symptoms and clinical interviews.\nBut, if biological tests for mental illness do come to fruition, even those already living with a condition could benefit.\nDr. Sabine Bahn, a professor of neurotechnology at Cambridge University, leads a team researching this premise.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not perform any head-to-head comparisons between traditional diagnostic methods and biological testing, but we feel the framing of the story gets the point across that there are traditional ways of diagnosing these disorders and a promising wave of new biological tests.", "answer": 1}, {"article": "Immunotherapy usually starts with clinicians harvesting immune system cells called T cells that have attached themselves to a tumor in an effort to attack.\nThe researchers hoped that by choosing T cells more selectively and cloning only those judged most likely to vanquish their foe, the treatment would be more effective.\nThe last step was to infuse the resulting army of cancer-fighting clones back into the patient.\nBut they also noted that the trial involved only 11 patients and said the therapy was less effective than in other published trials.\nSeveral independent researchers said the study results were promising.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Brief reference was made to one patient having had 6 years of chemotherapy \u201conly to have his melanoma return.\u201d And Rosenberg\u2019s comments at the end note a competing immunotherapy approach.\u00a0 But the story didn\u2019t give readers a clear context of melanoma treatments, or of why and for whom immunotherapy would be tried, etc.", "answer": 0}, {"article": "Like mifepristone, ella is a type of drug known as a selective progesterone receptor modulator (SPRM) that interferes with the hormone progesterone, which is critical for pregnancy.\nHRA is not seeking to sell ella without a doctor\u2019s prescription.\nIf it is approved, it should be clearly labeled as an abortifacient, which would limit its distribution, the American Association of Pro Life Obstetricians & Gynecologists said in a letter to the FDA earlier this month.\nIt was not clear what effect the drug had, if any, when a woman still became pregnant despite taking it, they added.\n\u201cThere is a medical need for an efficient emergency contraceptive product which acts consistently over a prolonged time period,\u201d HRA Pharma said in a separate document released by the FDA.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentions other emergency contraceptive options, it does not really describe the pluses and minuses of the new approach compared to the most important alternatives, Plan B or Mifeprex.1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n", "answer": 0}, {"article": "Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting up to 12% of women.\n\"If high irisin levels in teenagers with PCOS is established, this could lead to the development of treatments for PCOS.\n\"Teenagers who get an early diagnosis of PCOS can sooner start to deal with the physical and psychological symptoms caused by this lifelong condition,\" said lead researcher Dr Flora Bacopoulou.\nIn this study, Greek researchers from Aghia Sophia Children's Hospital in Athens compared the hormones of 23 teenagers with PCOS with 17 healthy teenagers of the same age and BMI.\nThey found that teenagers with PCOS had significantly higher irisin levels compared to the control group, and that this was associated with higher levels of the male sex hormone testosterone, a key marker of PCOS.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "So, what are alternative means of diagnosing PCOS? The release doesn\u2019t tell us. This is a particularly baffling oversight, since it would serve to place the research findings in context.\nA common method of diagnosing PCOS is measurement of total or free testosterone levels over time in teenagers with abnormal menstrual patterns. Measurement of testosterone levels can be challenging because of the low levels found in women and a lack of widespread access to reliable testing.\nThe release notes that \u201cDoctors are cautious when diagnosing PCOS in teenagers because the symptoms can be confused with normal pubertal changes\u201d and that \u201cthe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\u201d But the release never tells readers how PCOS is diagnosed. As noted above, according to the Mayo Clinic, there is no definitive means of diagnosing PCOS. Instead, diagnosis is made based on the results of a variety of tests and symptoms. By noting this, the release could have highlighted how useful an irisin-based diagnostic procedure might be \u2014 if it ever comes to pass.", "answer": 0}, {"article": "While heart disease is the leading cause of death in the United States, according to the Centers for Disease Control and Prevention, blacks have higher rates of cardiovascular disease and death than whites and the disease tends to occur earlier in life.\nParticipants taking 4,000 international units - more than six times the daily 600 IUs the Institute of Medicine currently recommends for most adults and children - received the most benefit, says Dr. Anas Raed, research resident in the MCG Department of Medicine and the study's first author.\nThe 4,000 upper-limit dose restored healthy blood level quicker - by eight weeks - and was also better at suppressing parathyroid hormone, which works against vitamin D's efforts to improve bone health by absorbing calcium, they reported.\nIn what appears to be the first randomized trial of its kind, they found that arterial stiffness was improved by vitamin D supplementation in a dose-response manner in this population, they write in the journal PLOS ONE.\nThe test essentially measures the speed at which the blood is moving, and in this case, fast is not good, Raed says.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not discuss any other options patients might have for dealing with arterial stiffness. It does note, however, that there are easy and inexpensive ways to add vitamin D to a person\u2019s diet.", "answer": 0}, {"article": "\"Human donor corneas work very well,\" Griffith said.\nThe next step in research, Griffith said, is to create a \"new generation\" of cornea implants and test them on a wider variety of patients.\nFor more than a century, doctors have considered transplantation of corneal tissue from deceased donors to be the best treatment, the study authors wrote.\nArtificial corneas are another option, but they're difficult to implant into the eye and can cause side effects, the researchers said.\nCurrently, some cornea patients get transplanted corneas from donors who have died.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does compare the treatment to human corneal transplants. It could have talked about plastic corneas, too. Dr. Mark J. Mannis, the one independent source in the story refers to a \"repertoire of corneal transplant surgeons.\" What else is in that repertoire? It would\u00a0be nice to know, and it would be even nicer to know how this procedure stacks up against the other options in terms of costs and benefits.\u00a0", "answer": 1}, {"article": "They set out to see if curcumin supplements could at least roll back that risk factor by enrolling 117 participants who had been diagnosed with metabolic syndrome for their study.\nThe researchers didn\u2019t examine the effect of curcumin on any diseases, and it was a fairly brief study, so it\u2019s not clear what the long-term implications may be they caution in their report.\nInflammation is also emerging as a feature of metabolic syndrome, Sahebkar\u2019s team writes in the journal Clinical Nutrition.\nIn the eight-week trial, researchers found significant reductions in signs of inflammation, such as C-reactive protein and other blood markers.\nAt the beginning of the study and again at the end, the researchers measured levels of three blood markers of inflammation, including C-reactive protein (CRP), which even on its own has been linked with heart disease risk.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any other medical interventions that can be used to reduce inflammation, such as corticosteroids or over-the-counter anti-inflammatories (e.g., ibuprofen). Statin drugs also reduce certain inflammation markers and are proven to reduce the risk of heart disease. However, these drugs weren\u2019t mentioned.", "answer": 0}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Tamoxifen is mentioned as the alternative to raloxifene.", "answer": 1}, {"article": "Breathing problems -- already a high risk because labor helps clear the baby's lungs of fluid -- happened four times as often in babies born at 37 weeks than those born at 39 weeks.\nThe findings from the study sponsored by the National Institute of Child Health and Human Development's Maternal Fetal Medicine Units Network also underscore the importance of a woman seeking medical care as early into her pregnancy as possible, so that doctors can accurately gauge the gestational age with an ultrasound, Mercer said.\nThe tests the doctors perform to determine the extent of the fetus's development are often not sophisticated enough to determine subtle milestones for breathing and processing food independently, said Dr. John Thorp, a University of North Carolina-Chapel Hill obstetrician and one of the authors of the study.\nA multisite study that appeared Thursday in the New England Journal of Medicine reinforces recommendations by the American College of Obstetricians and Gynecologists that discourage scheduling C-sections before 39 weeks of pregnancy unless there is documentation of lung maturity or it is medically necessary.\nMore than one-third of the surgeries performed during that time happened at 37 or 38 weeks.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Clearly vaginal labor after C-section is the alternative to elective repeat C-section. The story could have done more to discuss the pros and cons of vaginal delivery after C-section.", "answer": 1}, {"article": "Dominic Gessler lifts two squirming mice from their cages.\nScientists now argue it is our best, and perhaps only, chance at curing many diseases of the brain.\n\u201cAnd other than gene therapy, there was no other way.\u201d\n\nGene therapy is well-suited for treating inherited brain diseases.\nAAVs are not quite as efficient as adenoviruses at getting genes into human cells, but they are much safer: The human immune system barely notices the virus\u2019s outer coat or \u201cdress,\u201d as Gao calls it.\nGao did not always believe the drug would ever make it out of the laboratory, because the field of gene therapy has been plagued with seemingly insurmountable obstacles, including the deaths of test subjects.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story is explicit that at least some of the diseases mentioned have no alternative\u00a0treatments.\nHowever, we did want to note that only at the end does the story\u00a0explain\u00a0that this type of is\u00a0not appropriate for all conditions of the brain, especially those that involve multiple genes.\nWe would have preferred to have that read that at the\u00a0start of the story, to better balance the blanket statement in the headline (\u201cGENE THERAPY MIGHT BE THE BEST, AND PERHAPS ONLY, CHANCE AT CURING BRAIN DISEASES.\u201d)", "answer": 1}, {"article": "Assistant professor Mads Fiil Hjorth \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nEmail: madsfiil@nexs.ku.dk \n\nTel.\nThe latest findings, as published in AJCN, concluded that a personalized nutritional approach based on an individual's biomarkers will lead to improved weight loss and maintenance success.\nFor people with type 2 diabetes, the analysis found that a diet rich in healthy fats from plant sources would be effective for achieving weight loss.\nThe research analyzed data from three diet clinical trials which collectively looked at more than 1,200 individuals - Diet, Obesity, and Genes (DiOGenes); the OPUS Supermarket intervention (SHOPUS); and the Nutrient-gene interactions in human obesity (NUGENOB).\nThe different studies (six in total) employed a variety of nutrition strategies, including caloric restriction and ad libitum diets, varying the contributions of carbohydrate and fat, and increasing fiber intake.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that the researchers are looking at other types of biomarkers, including\u00a0gut microbiota, and at \u201cgenomics approaches\u201d that might aid in creating personalized diet plans.", "answer": 1}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story states that a control group in the study is receiving treatment with a drug called Sutent, and that patients receiving that drug are not faring as well as patients who receive both Bavencio and Inlyta. However, the story doesn\u2019t address whether any patients were receiving both Bavencio and Sutent, nor does it address any other potential treatments for advanced renal cell carcinoma. Are there even other treatment options available? The story doesn\u2019t say.", "answer": 0}, {"article": "This benefit is thought to come from the omega-3 fatty acids in fish, although studies of fish oil supplements have produced disappointing results in people who already have Alzheimer's.\nRaji presented the findings here at the annual meeting of the Radiological Society of North America.\n\"More fish, more brain, less Alzheimer's,\" he tells WebMD.\n\"The new study is the first to establish a direct relationship between fish consumption, brain structure, and Alzheimer's risk,\" Raji says.\nNov. 30, 2011 (Chicago) -- Older people who eat baked or broiled fish at least once a week may be boosting their brain health.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story at least hinted at \u201cother risk factors for memory loss that could affect the results, including age, gender, education, obesity and physical activity.\u201d\n ", "answer": 1}, {"article": "The group that received standard education lowered their scores by an average of 1 point.\nThe caveat, according to Spira, is that this study tested that specific program.\nBy the end of the study, the mindfulness group was showing a significant improvement -- shaving about three points, on average, from their scores on the sleep-problem scale.\nThe program, Black said, did not specifically address sleep -- a topic that might only stir anxiety in people who are already worried about a lack of sleep.\nBut he also emphasized the structured nature of the program tested in his study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This aspect of the story was great.\u00a0In the fifth sentence, the story makes a comparison to alternatives, saying, that on \u201caverage, the effects of the mindfulness program were comparable to what\u2019s been seen in studies of sleep medications and \u2018talk therapy.\u2019\u201d it makes the same comparison in more detail later in the story and in discussing the availability of different therapies.", "answer": 1}, {"article": "For example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\nMarch 20, 2011 -- Elevated levels of a group of five amino acids may predict the development of diabetes years before any noticeable symptoms occur, according to a new study.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s no new approach yet, but, the story does\u00a0present this research as a step toward a new type of screening. The headline says, \u201cBlood Test May Predict Risk of Diabetes.\u201d With that in mind, we think important contextual informatoin was missed. There should have been some comparison to other biometric models that are in the literature and used to identify patients at high risk for developing diabetes. Also, it would have been good to put this new evidence in context with what doctors already know. Many biomarkers are known to be predictors of diabetes. What you would like to know is once these other factors have been taken into consideration, how did this amino acid screen improve on those techniques?", "answer": 0}, {"article": "Highlighting the significance of the findings, the study\u2019s senior author, George A. Macones, MD, the Mitchell and Elaine Yanow Professor and head of the Department of Obstetrics and Gynecology, said, \u201cThis study is a tremendous addition to the literature on preventing surgical-site infections after cesarean.\nBut according to Tuuli, the unique circumstances of a C-section \u2014 that bacteria come from both skin and vagina and that a woman\u2019s immune system is altered during pregnancy \u2014 mean the results of these studies may not apply.\nThe researchers argue that the evidence is strong enough to change standard skin-prep practices for C-sections.\nRather than prepping patients with iodine-alcohol \u2014 a common antiseptic combination in C-sections \u2014 the research indicates that chlorhexidine-alcohol is significantly more effective.\nThe investigators pointed out that all other standard procedures for reducing the risk of infection after surgery, including giving preventive antibiotics beforehand, were the same in both groups.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The study compares an alternative method of skin preparation to the current standard and also mentions antibiotics.\u00a0Soap and water could be another alternative, as could foregoing an elective C-section, but it\u2019s probably too big a digression to mention these when reporting on a head-to-head study on antiseptics.", "answer": 1}, {"article": "They all drank caffeine regularly.\nTo the age-old question \u201cIs coffee bad for you?\u201d, researchers are in more agreement than ever that the answer is a resounding \u201cno.\u201d A new study published in the journal found that older people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\nIn fact, inflammation is an important function of the immune system, which uses it to fight off infections and remove potentially toxic compounds.\nIn an upcoming study, Furman and others will soon investigate the immune systems of 1,000 people; he hopes to use that information to develop a reference range of immune-system components to tell people whether their levels are normal, or if they\u2019re at higher risk for developing chronic conditions driven by inflammation.\nWe are able to point, with a much higher resolution picture, at aging and the things that should be markers for inflammation.\u201d\n\nThe key will be to figure out when the inflammatory response starts to spiral out of control.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are a wide variety of drugs available to treat various forms of inflammation, none of which are addressed. In the context of treating inflammation to ward off disease, some drugs are particularly worth mentioning. For example, the National Cancer Institute notes that \u201cMany studies have investigated whether anti-inflammatory medications, such as aspirin or non-steroidal anti-inflammatory drugs, reduce the risk of cancer. However, a clear answer is not yet available.\u201d By the same token, given the story\u2019s focus on coffee consumption, it might have been worth exploring other vehicles for caffeine consumption, such as tea or soda \u2014 particularly given that different caffeinated foods and beverages can include widely varying amounts of sodium, sugars or fats that can impact how \u201chealthy\u201d they are.", "answer": 0}, {"article": "Women can delay having their first Pap test for cervical cancer until they turn 21 and many can wait longer to go back for follow-up screenings, according to new guidelines released Friday by a major medical group.\n\"More testing is not always more intelligent testing.\"\n\"But we don't have any concerns that women are being asked to give up something that is helpful.\nThe American Cancer Society, which has led the opposition to the mammography guidelines issued by the U.S. Preventive Services Task Force, was involved in the discussions leading up to the Pap test guidelines and will consider them in reevaluating its own recommendations, an official said.\nThe change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story describes the new guidelines in layman\u2019s terms, and briefly describes the old ones. It makes it difficult for the reader to find and digest this information, however.\u00a0 \nIt should have indicated the risks of not getting screened at all.\u00a0 ", "answer": 0}, {"article": ".\nA product called the OFF!\u00ae Clip-On\u2122 repellent device could be an effective tool for preventing bites from the Aedes aegypti mosquito -- the primary vector of Zika, chikungunya, dengue, and yellow fever -- according to an article in the Journal of Medical Entomology.\nClip-On caused high mosquito mortality and knockdown rates up to 0.3 meters from the device, enough to protect a single person wearing the device.\nIn order to test the effectiveness of the device, Christopher Bibbs and Rui-De Xue of the Anastasia Mosquito Control District in Florida studied how the device performed against hungry Aedes aegypti mosquitoes.\nClip-On repels mosquitoes by releasing a vapor form of insecticide through a battery-powered fan, forming an insecticide \"cloud\" around the wearer of the device.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "In the release a study co-author is quoted scoffing at some of the alternatives, but without providing any comparison data. \u201cJust look at all the bug zappers, repellent bracelets, sonic bug repellents, and other zany creations that wax and wane in popularity,\u201d he said. Earlier reviewers also scoffed at this device.\nThe release should have mentioned somewhere that the alternatives aren\u2019t all \u201czany.\u201d For example, spray on bug repellent with the chemical DEET is widely recognized as an effective way to prevent mosquito bites.", "answer": 0}, {"article": "\"It's not something we'd recommend at this stage for the general population,\" Damian said.\nResults of the study are being presented at the annual meeting of the American Society of Clinical Oncology later this month.\nA new study could change the way doctors treat patients at high risk for skin cancer.\nFor the study, researchers in Australia looked at nearly 400 people who had had at least two non-melanoma skin cancers.\nResearchers found that a form of vitamin B3 called nicotinamide could help reduce the chance of skin cancer recurring in patients who've had it before.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Tried-and-true skin cancer prevention methods \u2014 e.g. limiting exposure, using shade, and applying sunscreen \u2014 aren\u2019t mentioned. We\u2019re also told that basal and squamous skin cancers are typically treatable, but not how. It would have helped this article to mention cryogenic freezing, radiation, and surgical removal as ways to treat those cancers.", "answer": 0}, {"article": "\"Doing that could be a lot easier than nudging children about going to bed,\" Raine said.\nIn addition, increased fish consumption was associated with fewer disturbances of sleep, which the researchers say indicates better overall sleep quality.\nFinally, the researchers controlled for demographic information, including parental education, occupation and marital status and number of children in the home.\nAnalyzing these data points, the Penn team found that children who reported eating fish weekly scored 4.8 points higher on the IQ exams than those who said they \"seldom\" or \"never\" consumed fish.\nPrevious studies showed a relationship between omega-3s, the fatty acids in many types of fish, and improved intelligence, as well as omega-3s and better sleep.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The important question about the role of omega-3s supplementation versus fish consumption was mentioned, but there were no details how the supplements compared in IQ or sleep improvements.", "answer": 0}, {"article": "Dennis Halmi, a member of the Bluepoint Surgical Group in Woodbridge, says that in 2002 \"we did a handful\" of second operations on obesity patients, \"maybe five, six.\nNot enough time has elapsed since the advent of second operations to get a long-term assessment.\nOf course, a second obesity surgery comes with increased risk.\nThe band is shaped like a little life preserver that can fill and go slack.\nIt's not always clear why.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story failed to provide indications about other surgical and medical options available to assist individuals with weight loss and maintenance following gastric bypass.", "answer": 0}, {"article": "An enzyme is a protein that performs a chemical reaction.\nA new study, however, offers some potential for hope.\nFRIDAY, Feb. 8, 2013 (HealthDay News) -- For people with celiac disease, everyday foods such as bread, pizza crust and muffins are potential enemies.\nSome experts identified limitations to the research.\nThe only current treatment for celiac disease is a gluten-free diet.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "A gluten-free diet is the only effective alternative for celiac disease. The story makes this clear.", "answer": 1}, {"article": "\u2022 None New guidelines outline how to handle back pain \n\n\n\nIn the study, 320 adults with moderate to severe back pain received one of three approaches over 12 weeks:\n\u2022 Education about how to cope with back pain\n\n\n\nYoga was just as effective as physical therapy -- and both groups were about 20 percent less likely to use pain medication than patients receiving education alone.\nOne person who might agree is 74-year-old Judith Zaborowski, who took up yoga more than 10 years ago to help with her aching back.\nDr. Robert Saper at Boston Medical Center is one of the authors.\n\"Yoga was as effective as physical therapy for reducing pain intensity,\" Saper said.\nHe explained the results.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story was about three alternative therapies for chronic low back pain\u2013physical therapy, education, and yoga. While a lot more could have been said on the effectiveness of these treatments, it was at least clear that there are options beyond yoga.", "answer": 1}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story at least mentioned that until now patients took \u201cmedicines that only tackled the symptoms of the disease, such as antibiotics to treat the infections. Patients typically spent a few hours each day wearing vibrating vests to dislodge mucus build-up.\u201d\u00a0 But there was no comparison of the effectiveness of the new drug with this past approaches.", "answer": 0}, {"article": ".\nImportantly, the researchers show that the prebiotic induced specific gut bacterial shifts compared to placebo.\n\"Powdered fiber, mixed in a water bottle, taken once a day is all we asked the children to change, and we got, what we consider, some pretty exciting results -- it has been fantastic,\" added Raylene A. Reimer, PhD, RD, professor and researcher in the Faculty of Kinesiology at University of Calgary, who led the study.\nBased on four-month intervention data, the annual projected body weight increase in the prebiotic group would be 3 kilograms (6.6 pounds), within the expected healthy range, whereas the projected increase in the placebo group was 8 kilograms (17.6 pounds), almost triple the expected yearly weight increase.\nThis is the first randomized controlled study to assess comprehensive changes in gut microbial composition with prebiotic intervention in children who are overweight and obese.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release didn\u2019t mention any other alternatives for reducing childhood obesity such as diets, exercise and nutrition education. We also aren\u2019t told whether any of the volunteers engaged in any of these alternative strategies during the time of the study and, if so, what impact they might have had on the results.", "answer": 0}, {"article": "Babies who are anemic often appear tired and pale.\nCutting the cord is a momentous event in a baby's life.\nNow, research suggests there may be benefits to keeping mom and baby attached a few minutes longer.\nAndersson's study marks the first time researchers have followed children to see whether the clamping makes a difference later in life.\nThose benefits, researchers say, likely have to do with iron.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There\u2019s either early or late clamping, and the article describes both methods", "answer": 1}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\n\"There is a large group in the middle called intermediate risk, which may be as much as 50% of the population,\" said Dr. Erin Michos, a cardiologist at the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins University\n\nA good candidate for a coronary calcium scan, she says, would be a 50-year-old man with slightly elevated cholesterol and a father who had a heart attack.\nOne large federally funded study found the coronary calcium score a better predictor of coronary events like a heart attack than the traditional Framingham Risk Score, which considers age, cigarette smoking, blood pressure, total cholesterol and HDL, the \"good\" cholesterol.\nThese new tests give patients a chance to make major changes in their diet and lifestyle, and give doctors an opportunity to treat them with medication.\n(CNN) -- Most heart attacks strike with no warning, but doctors now have a clearer picture than ever before of who is most likely to have one, says Dr. Arthur Agatston, a Miami cardiologist and author of the best-selling South Beach diet books.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The premise of this story is that screening tests can make a dramatic difference in heart disease. In reality, the tests may offer an incremental improvement in predicting risk among certain people who fall into a gray middle zone of risk based on conventional methods. There is a reference to the use of these tests in people with intermedicate risk, but the broad claims at the beginning and end of this story overwhelm any reasonable comparison between the touted tests and established alternatives. The story mentions diet and lifestyle changes only in the context of a claim that these tests \u201cgive patients a chance to make major changes in their diet and lifestyle.\u201d The story fails to note that people routinely stick to bad habits even when told they have a high risk of health problems or that since improving diet and lifestyle has benefits for everyone, an alternative approach would be to focus more effort and attention on effective strategies for changing behavior.", "answer": 0}, {"article": "This is a way of getting closer to an answer,\" said Weiner.\nWhile diagnosis by proton magnetic resonance spectroscopy is under study for early detection , accurate early detection by such noninvasive means is a ways away.\nLast week, the FDA approved an agent called Florbetapir F 18 injection (to be marketed as Amyvid), which will allow physicians using a positron emissions tomography (PET) scan to detect the presence and extent of amyloid plaques in patients concerned about declining mental function.\nOnce that happens, physicians, researchers and insurers will need to figure out who should get the test and at what cost, and who will pay.\nWith growing understanding that the changes of Alzheimer's disease may be decades in the making, the value of early detection is gaining adherents, said Weiner.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions the existence of at least one similar agent that is being tested as a diagnostic aid. Other approaches, such as testing for biomarkers of Alzheimer\u2019s disease in spinal fluid, are also in the works.", "answer": 1}, {"article": ".\nDr. Brennan cautions that while this study uses a larger sample than most, further studies are warranted.\nHowever, \"this study suggests dry needling as an effective alternative to cortisone injection.\"\n\"Evidence for dry needling of the hip in lieu of steroid injection is in its infancy,\" acknowledges lead author Kindyle L. Brennan, PT, PhD, with Baylor Scott & White Health.\nDr. Brennan adds that, \"The potential detrimental side effects of steroid injection, particularly repeated injections, are of concern for patients and providers alike.\"\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release adequately compares dry needling with steroid injections. Still, it could have mentioned other strategies for managing chronic hip pain such as physical therapy.", "answer": 1}, {"article": "Inflammation strips the myelin coating from nerve cell extensions, called axons, and connections at the ends of nerves, called synapses, are lost, together disrupting signaling and eventually causing permanent disability depending on where this occurs.\nIn addition to senior author Dr. Rhonda Voskuhl, who directs UCLA's Multiple Sclerosis Program and holds the Jack H. Skirball Chair in Multiple Sclerosis Research, study co-first authors were Noriko Itoh, Yuichiro Itoh, and Alessia Tassoni, with other co-authors including Emily Ren, Max Kaito, Ai Ohno, Vista Farkhondeh, Hadley Johnsonbaugh, Yan Ao, Josh Burda and Michael Sofroniew, all of UCLA.\nThe work was supported with funding from the Conrad N. Hilton Foundation, the National Institutes of Health, the California Community Foundation, the Tom Sherak MS Hope Foundation, the Rhoda Goetz Foundation for Multiple Sclerosis, and other partners of the UCLA Multiple Sclerosis Program.\nThe study is published in the Proceedings of the National Academy of Sciences.\nWorking with a mouse model of MS, the research team assessed astrocytes in various regions of the brain and spinal cord known to be involved in walking, vision or cognition.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not explain the ways that human patients with multiple sclerosis are treated currently, nor does it explain the existing research context clearly. If the small study is showing a new path for research, we need the context that says \u201cup until now, all the research was done in X way.\u201d We aren\u2019t given that here.", "answer": 0}, {"article": "Benign prostate hyperplasia, also known as enlarged prostate, is a non-cancerous condition familiar to millions of aging males.\nAnd while this study showed some symptomatic improvement, it didn't have enough objective data to show that the new technique would surpass surgery, she said.\nSince the study is being presented at a medical meeting and has not yet been published in a peer-reviewed journal, the findings should be considered preliminary.\nHowever, the authors did not see as great an improvement in \"urodynamic\" results, such as improved flow rate of the urine, which would indicate how well the bladder and urethra are performing; in this area, the patients did not improve as much as those who underwent TURP surgery, they noted.\n\"PAE is potentially fraught with complications,\" Lowe said, adding that the study follow-up of less than one year was short for a disease that lasts decades.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story provided some insight about how this new minimally invasive treatment for benign prostatic hyperplasia compared with TURP. \u00a0However it neglected to mention that there are number of surgical techniques and minimally invasive techniques available for which there is comparable effectiveness and fewer complications than TURP. \u00a0And while the study authors claim the new procedure has value because it didn\u2019t have the higher risk for the need for re-operation, the 9-month follow-up was too short to actually be able to lay claim to this benefit.\nThe oddest part of the story was the line that other minimally invasive treatments \u201care less effective and have a greater risk of a need for reoperation according to background materials that accompanied the study. (emphasis added)\u00a0 Does that mean according to marketing materials provided?\u00a0 What was that source of that material?\u00a0 What a silly, unsubstantiated, unsourced thing to include!", "answer": 0}, {"article": "\u201cThe rate was remarkably lower,\u201d Arnett told Reuters Health.\n\u201cAlthough this was not a randomized trial and there was no comparison group to assess whether specialized units performed better than nonspecialized (stroke) units, these (newly-reported) risks are substantially lower than expected.\nMore than two thirds of the patients in the study had a score of 4 or higher but the researchers caution that \u201climiting urgent assessment to patients with a score of 4 or more would miss approximately 20 percent of those with early recurrent strokes.\u201d\nThe study was also noteworthy because, over the long haul, patients did a particularly good job of taking the medications they were given.\nThe ongoing study, which used previous stroke estimates for comparison, was based on data from 4,789 patients from TIAregistry.org, an international registry designed to follow cases for as long as five years.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The intervention in this story is sending patients to hospitals with specialized TIA units. The alternative\u2013presumably being treated at a hospital without a TIA unit\u2013wasn\u2019t directly studied here, and this is made clear in the story.\nHowever, we do wish the\u00a0story had discussed if receiving care at one of these specialized units is really necessary, i.e., if similar care\u00a0can be received at a regular hospital. As the study noted, it appears so: The researchers stated that these results \u201cmay be achievable in a large range of settings as long as patients are evaluated and treated for acute TIA and minor stroke on an urgent basis.\u201d", "answer": 1}, {"article": "Individuals with panic chronically hyperventilate, even when not experiencing a panic attack.\nNinety percent of patients in this study experienced a significant improvement in PTSD symptoms at two months and six months post-treatment.\nEarly data from a fifth study reported on Freespira treatment for patients with Post-Traumatic Stress Disorder (PTSD).\nSymposium Chair David Tolin, Ph.D., Director of Anxiety Disorders Center, The Institute of Living, and Adjunct Professor of Psychiatry, Yale University School of Medicine, commented, \"Studies of the Freespira treatment have shown that this innovative approach to treating patients suffering from panic symptoms and panic attacks not only significantly reduces or eliminates these symptoms in approximately 80% of patients, but also results in meaningful reduction in health costs.\"\nA Symposium at the Anxiety and Depression Association of America (ADAA) Annual Conference in Washington, DC focused on the impact of abnormal breathing patterns on anxiety-related conditions and treatments as reported in five studies.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not discuss alternatives. Cognitive behavioral therapy, medications and startegies for managing stress are all known therapies for anxiety disorders. The release did not compare effectiveness of the device therapy with any other known therapies.", "answer": 0}, {"article": "A group of 1,537 women were randomly assigned to a daily diet that included five vegetable servings, three fruit servings, 16 ounces of vegetable juice and 30 grams of fiber.\nResearchers noted that none of the breast cancer survivors lost weight on either diet.\nDuring the next seven years, the cancer returned in 256 women (16.7 percent) in the special diet group and 262 women (16.9 percent) in the comparison group.\nThat led some experts to suggest that weight loss and exercise should be the next frontier for cancer prevention research.\nHopes that a diet low in fat and chock-full of fruit and vegetables might prevent the return of breast cancer have been dashed by a seven-year experiment in more than 3,000 women.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story failed to mention other breast cancer recurrence strategies such as hormone and biological medications, etc. Other studies have suggested that weight management via diet and exercise may play a role in the prevention of certain types of breast cancer in post-menopausal women\u00a0 (e.g hormone receptor negative). The story did mention prevention of excessive weight gain via diet and exercise would be the \"next frontier in cancer prevention research\".\u00a0 ", "answer": 0}, {"article": "Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.\nIn the U.S., the CoolSculpting procedure is FDA-cleared for the treatment of visible fat bulges in the submental area, thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm.\nThe CoolSculpting procedure is not a treatment for obesity.\n\"A 2017 American Society for Dermatologic Surgery (ASDS) survey revealed that 73 percent of patients are bothered by excess fat under the chin.2 We are pleased this patient concern can successfully be addressed by CoolSculpting through a non-invasive approach, and furthermore improve the appearance of lax tissue in the treated area.\"\nYou should not have the CoolSculpting procedure if you suffer from cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release is silent on alternative approaches which is why we rate this one Not Satisfactory\nDouble chins are often associated with weight gain. Therefore, most people can get rid of double chins through a healthy lifestyle, like a nutritious diet and regular exercise.\nThere\u2019s anecdotal evidence that chin exercises could help eliminate double chins, like holding a ball under your chin, puckering your lips while looking at the ceiling and stretching your tongue in various directions.\nOther approaches include mesotherapy, which delivers fat-dissolving substances through a series of injections.", "answer": 0}, {"article": "Professor Marianne Thoresen said: \"Even if we account for a lesser severity of perinatal asphyxia, our research has shown that therapeutic hypothermia reduces the number of children who develop epilepsy later in childhood.\nEven if a lesser severity of perinatal asphyxia is accounted for, cooling therapy has increased the number of healthy survivors and there are very few children with epilepsy needing drug treatment.\nUntil recently, 20 to 30 per cent of these patients would develop epilepsy and many need regular antiepileptic treatment.\nIt is known that newborn babies who suffer perinatal asphyxia may develop permanent brain injury resulting in cerebral palsy or other conditions, like epilepsy.\nCooling babies deprived of oxygen at birth (perinatal asphyxia) can reduce the number of children who develop epilepsy later in childhood, according to a new study published in the journal Epilepsia.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Therapeutic hypothermia is the only widely accepted preventative treatment for brain injury from neonatal asphyxia. Some researchers have experimented with antioxidants, and general improvements in care (such as adjusting ventilators to avoid too much oxygen) may help neurologic outcomes.\nThere are other treatment options that can be used in conjunction with induced hypothermia, but none that would be used as an alternative to induced hypothermia when it comes to mitigating potential neural damage. As such, even though it doesn\u2019t list alternatives, we\u2019ll rate this Satisfactory.", "answer": 1}, {"article": "People with hypertension have traditionally been advised to stay away from alcohol because excessive drinking can increase blood pressure.\nAnd, one of the study authors, Eric Rimm of the Harvard School of Public Health, has been sponsored by the Distilled Spirits Council of the United States to speak at academic conferences.\nThe forthcoming study on men doesn't include an MRI component needed for a more complete comparison.\nCAUTIONS: The study included only male healthcare providers, so it might not be generalizable to a broader population.\nAn international team of researchers led by Dr. Kenneth Mukamal and Joline Beulens sought to find out how moderate drinking affects cardiovascular disease in people with high blood pressure.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not mention any alternatives to reduce cardiovascular disease risk.", "answer": 0}, {"article": "Common symptoms in the aftermath of concussion include confusion, headache, changes in vision or hearing, thinking or memory problems, fatigue, sleep changes and mood changes.\n\"This is an exploratory, proof-of-concept study showing that we can identify patients soon after mild brain trauma who may have more persistent symptoms, despite no other evidence of injury within the brain,\" said Pratik Mukherjee, MD, PhD, professor of radiology and biomedical imaging at UCSF and the senior author of the study.\nAlthough effective drug treatments for mTBI await discovery, rest and counseling are known to be helpful for patients, Mukherjee said.\n\"We may be able to use this information to help guide treatment decisions and counseling of patients early on, when it may be more effective.\"\nIn their new study, published online January 13, 2017 in the Journal of Neurotrauma, the researchers used a technique called functional MRI (fMRI), coupled with sophisticated statistical analysis, to track activity in the brain networks of 75 patients, aged 18 to 55, within the first two weeks of their having experienced concussions.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release mentions that rest and counseling are helpful treatments for patients who suffered a concussion. However, effective primary drug treatments for mild traumatic brain injury don\u2019t yet exist, the release adds.\nDepending on the severity of the case, there are medications to limit secondary damage to the brain immediately following injury. These include diuretics to decrease pressure in the brain, anti-seizure drugs and coma-inducing drugs.\nWe feel the news release does an adequate job comparing alternatives, which is why we give it a Satisfactory rating.", "answer": 1}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The new device was compared with traditional 2-D mammography but, as already noted, the story did not compare the approaches on some meaningful measures such as rates of false positives or false negatives or biopsy rate for traditional vs. 3-D.", "answer": 0}, {"article": "\"This new shot may provide a more long-lasting approach, especially if it could be given once a month,\" Sacco said.\nFormer AHA President Dr. Ralph Sacco said that it is too early to make any predictions about what role, if any, this therapy will have in lowering cholesterol levels, but it could one day fill an important void.\nThe new drug did hit its target, PCSK9, and decreased levels of LDL cholesterol by up to 64 percent.\nStudy author Clapton Dias, medical sciences director of clinical pharmacology and early development at Amgen, in Thousand Oaks, Calif., said this shot could be given as an add-on to current cholesterol-lowering therapies for people who are not getting as low as they should be or as a standalone treatment for people who can't tolerate existing lipid-lowering drugs.\nCardiologists were cautiously optimistic about the novel therapy.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions healthy lifestyle changes and statin drugs as\u00a0established\u00a0ways to lower cholesterol. It could have mentioned other approaches \u2014 such as nonstatin\u00a0cholesterol-lowering\u00a0drugs as well as\u00a0special margarines fortified with plant sterols \u2014 that are sometimes\u00a0used to lower cholesterol.", "answer": 1}, {"article": "All rights reserved.\nIn the section of the article discussing management options for IBS, Dr. Enck and the accompanying panel of researchers stated \"peppermint oil\u2026is beneficial in reducing IBS symptoms.\"\nThe review team concluded that as a first-line therapy option, peppermint oil is superior to placebo in improving IBS symptoms and the risk of adverse events is no greater with peppermint oil than with a placebo.\nAdditionally, the support from the medical community builds on a previously important review article about the use of peppermint oil in IBS.\nAn international scientific and medical review team reported that there are a range of agents available to treat IBS and physicians should be knowledgeable about the efficacy and risk profile of any option they are about to prescribe.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The Nature review highlighted in the release refers to several other IBS treatments, including some  drugs such as otilonium bromide and hyoscine, that act to reduce spasm, as does peppermint oil. The release doesn\u2019t note these alternatives or several other drug, nutrition and behavioral approaches to managing IBS.", "answer": 0}, {"article": "To place an electronic embedded link to this study in your story: This link will be live at the embargo time: http://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2016.4219\n\nIn a study published online by JAMA Surgery, Daniel E. Hall, M.D., M.Div., M.H.Sc., of the Veterans Affairs Pittsburgh Healthcare System and University of Pittsburgh, and colleagues examined the effect of a Frailty Screening Initiative (FSI) on death and complications by comparing the surgical outcomes of patients treated before and after implementation of the FSI.\n\u201cThis study reveals the feasibility of facility-wide frailty screening in elective surgical populations.\n\u201cThe ultimate cause of the survival benefit is likely multifactorial, including changes in preoperative decision making, intraoperative management, and postoperative rescue,\u201d the authors write.\nEMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, NOVEMBER 30, 2016\n\nAlso available at the For the Media website, the commentary \u201cA Call for Frailty Screening in the Preoperative Setting,\u201d by Anne M. Suskind, M.D., M.S., and Emily Finlayson, M.D., M.S., of the University of California, San Francisco.\nOn the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient\u2019s frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release mentions no alternatives to this screening program but presumably there are other methods and techniques that are used to reduce harm done on frail people who undergo elective surgery. Since this is a \u201cbefore-after\u201d trial presumably there would be some kind of frailty assessment, even an informal one, that happens prior to surgery?", "answer": 0}, {"article": "Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure.\nKnowing the genotype helps inform treatment recommendations and the duration of treatment.\n\u201cThis approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C,\u201d said Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA\u2019s Center for Drug Evaluation and Research.\nThere are at least six distinct HCV genotypes, or strains, which are genetically distinct groups of the virus.\nResults demonstrated that 95\u201399 percent of patients who received Epclusa had no virus detected in the blood 12 weeks after finishing treatment, suggesting the patients\u2019 infections had been cured.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release explains in some detail that different HCV patients may follow different drug regimens, depending on their particular strain of virus and other characteristics of their infection. A bit more explanation about how patients and providers may choose whether to use Epclusa or other alternatives and how they will compare would have been helpful.", "answer": 1}, {"article": "Women whose cancers were detected by mammograms were more likely than the doctor- or patient-detected cancers to have lumpectomy or other breast-conserving surgery: 67 percent vs. 48 percent.\nWhen considering its recommendation, the task force took all available evidence into account, including published studies, Moyer noted.\nMalmgren, a breast cancer survivor, says more focus should be placed on the benefit of early diagnosis, because it often means less treatment is needed.\n\"A screening test, if it can't find something earlier than [by] clinical presentation, is a poor test,\" she said.\nHowever, she said, the study does not provide support for all women aged 40 to 49 to have routine mammograms.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "In allowing Dr. Virginia Moyer of the USPSTF to talk about the need for women \u201cto make their own decision,\u201d the story at least implies that declining screening is a choice.\u00a0 It could have been far more overt, but we\u2019ll give the story the benefit of the doubt that the alternative choice was at least implied.", "answer": 1}, {"article": "[3] Quote direct from author and cannot be found in text of Article.\nBut until now, information on the prognostic value of grip strength was limited, and mainly obtained from select high-income countries.\nFurther research is needed to establish whether efforts to improve muscle strength are likely to reduce an individual's risk of death and cardiovascular disease.\"\nLoss of grip strength is unlikely to lie on a single final common pathway for the adverse effects of ageing, but it might be a particularly good marker of underlying ageing processes, perhaps because of the rarity of muscle-specific diseases contributing to change in muscle function.\"\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release specifically notes that grip strength results are a stronger predictor of death than systolic blood pressure. But what about the most common ways that clinicians currently assess the health risks of patients, such as with\u00a0Framingham data and the related NHLBI heart risk assessment tool \u2014 free and online? \u00a0Call us picky, but\u00a0we can easily recall widespread news coverage of whether wrinkles in your earlobes can predict heart attack risk. \u00a0So we don\u2019t think it\u2019s unreasonable to expect some reference to an enduring, well-supported alternative to the risk predictor of the day.", "answer": 0}, {"article": "The procedure, called a prostatic urethral lift, does not improve flow as much as surgery, in which a physician cuts away some of the inside of the prostate to allow better flow. But the lift procedure and recovery are much quicker, with no hospital stay and fewer complications. And patients who get the sutures can always come back for surgery later.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are alternatives to prostatic urethral lift yet only one was\u00a0discussed with enough detail to be useful. We learn that the lift \u201cdoes not improve flow as much as surgery,\u201d but the \u201clift procedure and recovery are much quicker, with no hospital stay and fewer complications.\u201d Those who might not be adequately served by the urethral lift can always \u201ccome back for surgery later.\u201d", "answer": 0}, {"article": "All rights reserved.\nApproval as an initial treatment likely would boost that sharply.\nIt targets cancer cells more than healthy ones, Roychowdhury said.\nIf approved, Tykerb \u2013 known as Tyverb in Europe \u2013 will be used along with another drug that prevents hormones from making cancer cells multiply.\nTykerb had sales of $189 million last year.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While the story gave a brief description of hormone therapy combined with chemotherapy, it wrote these off as causing \"nasty side effects\" without giving any substantive data-driven comparison of this approach vs. Tykerb, whose side effects can be pretty \"nasty\" as well. ", "answer": 0}, {"article": "\u201cI don\u2019t want to throw cold water on an interesting thing, but that\u2019s what it is \u2014 an interesting thing,\u201d Gallo said.\n\u201cIt is possibly a cure, that\u2019s for sure, you won\u2019t know for absolute sure until the person dies and undergoes extreme PCR (genetic) analysis of post-mortem tissue.\u201d\n\nThe mutation affects a receptor, a cellular doorway, called CCR5, that the AIDS virus uses to get into the cells it infects.\nSome researchers are working on the idea of gene therapy to treat or try to cure HIV, but the technology is still in experimental stages.\n\u201cOur results strongly suggest that cure of HIV has been achieved in this patient,\u201d they wrote in the journal Blood.\nCocktails of strong drugs can suppress the virus, keeping patients healthy and reducing the chance they will infect others, but there is no vaccine.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The last sentence in the story reads \u201cCocktails of strong drugs can suppress the virus, keeping patients healthy and reducing the chance they will infect others, but there is no vaccine.\u201d We would have liked to have seen a little more on this point. The fact is, HIV infection is becoming more and more like a chronic disease because of the success of antiretroviral (ARV) therapies. The death rate from AIDS has plummeted, even in developing countries, over the past two decades. This means that, while a vaccine or another therapy that eliminated the virus post-infection would be a boon for humankind, it is not the only approach worth hailing. We would like to see more ink devoted to innovative attempts to stop the spread of HIV and to broadly apply ARVs in countries that already have a high concentration of infected adults and less attention given to one offs like this study.\u00a0We would have rated this as satisfactory if the story did not mention the vaccine issue. That expands the criterion into prevention and therefore into public health measures as comparators.", "answer": 0}, {"article": "\"They do research online, are more informed and sometimes go to the doctor demanding, 'I think I need an MRI.'\nBernstein says she sees lots of desperate patients like Bradford.\nShe acknowledges it's sometimes difficult to encourage a patient with cracking head pain to get up and exercise.\n\"\n\nAnd while an informed patient is a good thing, Mafi says sometimes the patient gets it wrong.\nThat testing is expensive, it may not be necessary and it could even be harmful, says lead researcher Dr. John Mafi, of Beth Israel Deaconess Medical Center in Boston.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions alternatives to medical or surgical treatment in the last two paragraphs of the story but it does not explain the relative benefits or harms of any approach.", "answer": 0}, {"article": "Treatment typically involves the use of inhaled steroids and bronchodilators to open airways and make breathing easier.\nIn a new study of 68 people with COPD, some got acupuncture, along with their daily medication, for three months.\nMany people with COPD have problems getting optimal nutrition because of their condition.\nThe study showed that acupuncture may improve stomach function, making it easier for people with COPD to eat a healthy diet and maintain a normal weight.\nPeople who received real acupuncture also showed improvements in their quality of life and ability to exercise, according to researchers from Kyoto University and Meiji University of Integrative Medicine in Kyoto, Japan.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not address any other alternative treatments for COPD, except acupuncture. The implication is that one can use standard meds or those meds plus acupuncture. There are other non-medicine treatments for COPD. If the mechanism for action is relaxation, there are also other forms of relaxation.", "answer": 0}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Although the story mentions neurologic exams, this is insufficient information on the alternatives. What are the advantages and disadvantages of PET scanning compared to existing approaches? How will the scanning fit in with current practice? These questions are not answered in the story.", "answer": 0}, {"article": "Infection with H. pylori is associated with increased risks of stomach and throat cancers.\nImmunochemical FOBT is now largely replacing the older test.\nAdvances in the stool tests in recent years have made them more effective.\nA screening colonoscopy averages around $3,000.\nPositive results on the screen prompt a follow-up colonoscopy to investigate the source of the blood.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Good comparisons between the newer FOBT test, the older stool test, and colonoscopy.", "answer": 1}, {"article": "The study was funded by the P.J.\nPreviously, the appropriate blood pressure treatment for these patients used risk calculations and some guesswork, potentially leaving many vulnerable to heart disease or taking drugs they don't need.\nThus, even though their calculated heart disease risk is relatively low and their blood pressure is below traditional cutoffs for treatment, the researchers say people in this category with calcium over 100 are high risk and may benefit from more aggressive blood pressure treatment.\nIn the study, published on Jan. 10 in Circulation, the researchers say these calcium scores allow physicians to go beyond the traditionally calculated risk factors to determine which blood pressure treatment strategy may be most appropriate for a particular patient.\n\"It may be that if patients are in that blood pressure treatment gray zone with a high risk score but their coronary artery calcium score is zero, then they don't need to be treated aggressively to 120 millimeters of mercury and can be treated to 140 instead,\" says McEvoy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release offers this comparison: \u201cPreviously, the appropriate blood pressure treatment for these patients used risk calculations and some guesswork, potentially leaving many vulnerable to heart disease or taking drugs they don\u2019t need.\u201d\nPrevious treatment guidelines (JNC 7) recommended only lifestyle changes for the average-risk prehypertensive patient. (And as noted above, the current guidelines do not include a prehypertensive category.) We would like to see some mention of these recommended lifestyle changes such as exercise, weight loss, dietary changes, and limiting alcohol, which can reduce blood pressure along with providing other health benefits.", "answer": 1}, {"article": "Asthma on the Rise in U.S.\nHe says it was accidentally discovered that kampo herbs could wipe out symptoms in many people while testing the ancient remedy against an allergic skin disorder known as atopic dermatitis.\nThe study did not look at possible side effects of kampo herbs.\nNorth American allergy experts tell WebMD that although they find the preliminary findings fascinating, further study is needed before they would recommend the herbs.\nSymptoms completely disappeared in 94% of patients taking kampo herbs after an average of 16 days, Shimoide says.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story was based on a comparison of kampo herbs and standard drug treatment.\u00a0 The story also mentioned that asthma can usually be controlled by avoiding asthma triggers and correctly using prescribed medications.", "answer": 1}, {"article": "Steroids can cause severe weight gain, acne and the weakening of bones, among other side effects.\nIn 2000, the company\u2019s share price soared to over $100 on anticipation that understanding the human DNA blueprint \u2014 the human genome \u2014 would lead to a cornucopia of drugs.\nMore patients on the drug had the required improvement in symptom severity.\nIt also changed the measurement of success and lengthened the trial to give the drug more time to work.\n\u201cThe question was, \u2018Can you prove in a very large trial what we\u2019ve proven here?\u2019 \u201d\n\nThe 865 patients in the trial, who were mainly in Asia, South America and Eastern Europe, received either Benlysta or a placebo in addition to the drugs they were already taking.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses that the medication reported on is used in addition to the typical treatments used for treating lupus. \u00a0It did not, however, provide any insight about which segment of the lupus patient population might benefit. \u00a0As such, it did not provide readers with sufficient information about when additional treatment with Benlysta might be considered.", "answer": 0}, {"article": "Jamie Stagl worries that women with breast cancer don\u2019t get enough help coping with their diagnosis.\nStagl doesn\u2019t know whether the women are still using the techniques they were taught \u2014 which include mindfulness, deep breathing, visual imagery, cognitive behavioral therapy, and learning how to ask for help from friends and family.\n\u201cThis is really a teachable moment.\u201d\n\nThe skills taught in the course are useful at many stressful moments, Porter said, not just when cancer is diagnosed.\nIf a woman\u2019s stress level remains high indefinitely after diagnosis, she may have a worse outcome than if she can bring it back down, Stagl said.\nThere\u2019s almost nothing more stressful.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses stress management in broad terms, referring to it as teaching patients \u201crelaxation techniques and coping strategies.\u201d It does not discuss other possible treatment options for dealing with stress or depression following serious illness, such as professional counseling or medications.", "answer": 0}, {"article": "Kilmer McCully of the V.A.\nThe findings follow a number of disappointing studies testing vitamins and other dietary supplements for health reasons.\nThe new study, involving more than 15,000 high-risk patients, did not find any overall benefit and even suggested the combination may be dangerous for some patients.\nThe new findings undermine a theory that taking B vitamins to reduce levels of an amino acid in the blood called homocysteine could protect against heart attacks and strokes.\nAlthough the new studies did show that the vitamins cut homocysteine levels, that did not translate into a reduction in the risk for heart attacks or strokes.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No other treatment options for lowering risk of heart attacks or strokes are mentioned.", "answer": 0}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions hysterectomy as the primary alternative.", "answer": 1}, {"article": "MS can cause many symptoms, including blurred vision, loss of balance, poor coordination, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, paralysis and blindness.\nA trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start, added Racke, who co-authored an editorial that accompanied the study.\nHe said, \"As neurologists battle with current therapies that are limited for progressive MS in younger patients, this study provides a possible new avenue for treatment.\"\nBut the treatment can be risky because the patient's immune system has to be wiped out before the stem cells are transplanted, the researchers said.\nThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that \u201cA trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start.\u201d The story also notes that \u201cMedications can slow the progression of MS and help patients manage symptoms, but there\u2019s no cure.\u201d", "answer": 1}, {"article": "Dr Davide Pellacani, who began these studies in York, before moving to the University of British Columbia, said: \"Using this computer analysis, not only could we see which tissue samples had cancer and which didn't, but also which cancers were dangerous and which ones less so.\nA team at the University of York and the University of British Columbia, Canada, however, have designed a test that can pick out life-threatening prostate cancers, with up to 92% accuracy.\nIt is believed that success rates could be hindered as a result of treating all prostate cancers in the same way.\nTo take this method out of the laboratory, the team are now investigating a further trial with new cancer samples, and hope to involve a commercial partner to allow this to be used for patients being treated in the NHS.\nScientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The alternatives to this test include other genomic tests; PSA, Gleason scores from biopsies, and MRI results, none of which are mentioned.\nThe release does say that this test could be an alternative to radiotherapy and surgery (by distinguishing non-aggressive from aggressive cancers), but it doesn\u2019t list any of the harms or benefits of other interventions. It also does not say what treatment options there are should a patient find that they have a non-aggressive form of cancer.", "answer": 0}, {"article": "They were divided in groups of 10.\n\u201cHowever, much more work needs to be done until we can say with certainty that it will tackle the disease in humans as mouse models don't always faithfully replicate the human disease.\nBrough, however, cautioned that further research is required to identify its impact on humans and the long-term implications.\nThe research was conducted when mice had developed memory problems.\n\u201cThere is experimental evidence now to strongly suggest that inflammation in the brain makes Alzheimer\u2019s disease worse.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions, near the top, \u201cno drug medications can successfully treat chronic neurodegenerative disease, but certain medicines can help alleviate symptoms or slow down\u00a0the progression.\u201d\u00a0This barest of nods toward alternatives earns it a just-passing Satisfactory rating.", "answer": 1}, {"article": "A popular new type of prenatal test intended to find genetic flaws in a fetus can in rare cases also reveal previously undiagnosed cancer in the mother.\n\nThe unexpected finding emerged in a study involving eight women who initially had abnormal results from the prenatal blood test, but for whom a subsequent assessment showed their babies were normal. When the mothers\u2019 DNA was reanalyzed, researchers said, the anomalies were linked to cancer in each of the women.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article explains nicely the major alternatives to the fetal blood tests and also mentions both companies that market the test.", "answer": 1}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions four other approaches to dealing with ocular melanoma, including monitoring without immediate treatment, implantation of a radioactive iodine chip, proton beam and gamma knife therapy (neither of which is explained), and surgery to remove either the tumor or the entire eye. This is sufficient to merit a satisfactory rating.\nIt would have been useful\u00a0to highlight the existing options\u2013and quantify the outcomes\u2013so readers would have a sense of what we goals we would be shooting for with a new treatment. Also, we also took issue with how the story frames the existing treatment\u00a0for ocular melanoma by highlighting its negative side effects in one famous patient (Oliver Sacks) against the experimental therapy\u2019s potential, which is still only based on animal studies.", "answer": 1}, {"article": "\"In conclusion, gemcitabine did not result in improved overall survival compared with fluorouracil plus folinic acid in patients with [surgically removed] pancreatic cancer,\" the authors concluded in their report.\nAnd even for those, unfortunately 75 to 80 percent of those will go on to recur even after the surgery appears to be successful.\n\"But the point is that pancreatic cancer is a terrible disease, and really just a minority of patients are candidates for surgery.\nThe finding, reported in the Sept. 8 issue of the Journal of the American Medical Association, stems from work conducted by Dr. John P. Neoptolemos, of the Cancer Research U.K. Liverpool Cancer Trials Unit at the University of Liverpool in England, and colleagues.\nThe pool of nearly 1,100 patients that the researchers focused on were part of the large European Study Group for Pancreatic Cancer trial that took place across 159 pancreatic cancer centers located in Europe, Canada, Australasia and Japan.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story details the comparison between two approaches. It wasn\u2019t exactly clear about whether either was \u201cnew\u201d vs \u201cexisting,\u201d but, in fact, they are both existing approaches, with the one positioned as the \u201cnewer\u201d approach, gemcitabine, currently the preferred agent according to the JAMA editorial. While we would have loved more clarity about the reason why the study compared these two approaches, overall, the comparative nature and tone of the story are clear and seem appropriate.", "answer": 1}, {"article": "The best performers included amitriptyline and escitalopram, while the worst included fluoxetine\u2014commonly sold under the trade name Prozac\u2014and reboxetine, which is not approved for sale in the U.S.\nThe study results represent the most comprehensive evidence currently available, they wrote.\nExperts not involved in the research agreed the results were significant.\nWhile these results should reassure many people with depression that antidepressants can be effective, \u201cthis does not necessarily mean antidepressants should always be the first line of treatment,\u201d he said.\nJames Warner, an Imperial College London psychiatrist, added: \u201cDepression causes misery to countless thousands every year and this study adds to the existing evidence that effective treatments are available.\u201d\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story discusses the other major treatment approach for people with depression \u2014 talk therapy.", "answer": 1}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions that this hormone therapy to prevent breast cancer recurrence is in addition to surgery. Tamoxifen, another hormone therapy, is also mentioned. ", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Story explains why researchers thought adding clopidogrel to aspirin might be helpful in a broader group of people.", "answer": 1}, {"article": "Even the ancient Egyptians used the natural form of it for pain relief centuries ago.\n\"This study found strong evidence that aspirin use may reduce cancer death.\nCao hopes her study will continue to broaden the body of research to include cancer-related deaths overall.\nNext, her group hopes to study what specific groups may most benefit from this practice, particularly based on those individuals with varying cancer risk.\nTherefore the findings are believed to be very robust, and suggest that aspirin, which is widely available, cheap and has limited toxicity, has the potential to have widespread benefit on cancer mortality for breast, colon, lung and prostate cancer.\"\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "No alternative approaches are included in this story. Cancer screening and lifestyle changes could have been included, for example, as evidence-based methods for lowering death risks of some types of cancer.", "answer": 0}, {"article": "Instead, they pass through to the large intestine, where they draw water into the gut and start to ferment.\n\u201cFollowing strictly the low-FODMAP diet is associated with changes in the microbiota that many would not equate with good health,\u201d says Gibson, who stresses that a low-FODMAP diet should be used to reduce specific symptoms, not as a way to improve health.\nIf your gut can handle FODMAPs, foods that contain a lot of them can be very good choices \u2014 partly because the fermentation helps your gut biome and partly because the way FODMAPs are digested means you\u2019re absorbing fewer calories than indicated on a FODMAP-rich product\u2019s label.\nGibson estimates that, overall, about 10 percent of the population may be FODMAP-sensitive.\nThey may assume that they have gluten sensitivity, but some researchers believe that it\u2019s not the gluten they\u2019re sensitive to.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "An elimination diet \u2014 where foods are systematically removed and then reintroduced to the diet in order to see which ones are causing problems \u2014 is considered by many to be the most effective approach to treating people with suspected food sensitivities. People diagnosed with irritable bowel syndrome may also be treated with a variety of medications. The story doesn\u2019t really address any of the other options available for people with food sensitivities or IBS.", "answer": 0}, {"article": "In a similar study published in the journal Pediatrics in 2004, researchers recruited 100 children with upper respiratory tract infections who had been coughing for an average of over three days.\nThe thinking is that sweet substances of any kind help soothe the back of the throat and break up mucus in the airways.\nUltimately, the honey produced the greatest improvements when it came to better sleep and reduced cough frequency and severity.\nIn this occasional series, the New York Times \u201cReally?\u201d columnist, Anahad O\u2019Connor, explores the claims and the science behind alternative remedies that you may want to consider for your family medicine cabinet.\nNatural remedies have an obvious appeal, but how do you know which ones to choose and whether the claims are backed by science?\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job comparing and contrasting the different remedies. We wish it had provided real numbers, but, overall, it did a good job.", "answer": 1}, {"article": "Feb. 2, 2011 -- The human papillomavirus (HPV) vaccine can help stave off genital warts in boys and men, according to a new study in the Feb. 3 issue of the New England Journal of Medicine.\nThese vaccines are now on the CDC\u2019s routine childhood vaccine schedule for girls starting at age 9.\n\u201cThe most salient message is that the [Gardasil] vaccine can prevent HPV infection on the external genital region, which means that we can now prevent most cases of genital warts if the boy is vaccinated at a sufficiently early age,\u201d says study researcher Joel Palefsky, MD, a professor of medicine at the University of California, San Francisco.\nThe vaccine is recommended for optional use in boys and men.\nBoth of these vaccines are recommended to prevent cervical cancers.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Althought far from perfect as a preventive, the use of condoms should have been given some space in the story; along with limiting the number of sexual partners or abstinence.", "answer": 0}, {"article": "\u201cNow we know that electrical impulses to the olfactory bulb can provide a sense of smell \u2014 and that\u2019s encouraging.\u201d\n\nIn addition to Dr. Holbrook, authors on the International Forum of Allergy & Rhinology study include co-first author Sidharth V. Puram, MD, PhD, of Washington University School of Medicine, Reiner B.\nThe findings described in the International Forum of Allergy & Rhinology report demonstrate this feasibility.\nIn the report, the researchers describe endoscopic procedures to position electrodes in the sinus cavities of five patients with an intact ability to smell.\nReporting online today in International Forum of Allergy & Rhinology, the research team describes their results, which provide a proof of concept for efforts to develop implant technology to return the sense of smell to those who have lost it.\nThere are currently no proven therapies for these cases.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release notes that some cases of anosmia can be treated, but that there are no proven therapies for treating anosmia cases caused by nerve damage. The release also mentions preliminary work being done at another university aimed at developing a treatment for patients with anosmia caused by nerve damage (that work is also in its earliest stages). That earns it a satisfactory rating here.", "answer": 1}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The study itself was a comparison of two different placebos \u2014 one cheap, the other expensive. The story makes this clear.", "answer": 1}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story at least mentions the existence of other alternatives for risk assessment, such as the\u00a0Framingham Risk Score.\u00a0But it doesn\u2019t really explain how this test differs from those other risk measures. We\u2019ll give the story the benefit of the doubt here.", "answer": 1}, {"article": "Furthermore, erectile dysfunction is reported in 21 to 85 percent of all prostate cancer patients, while urinary incontinence is reported in 24 percent of men with this disease.\nThis trial represents an expansion of the Abramson Cancer Center's integrative medicine and wellness services that are available to patients and survivors.\nThe new, first-of-its-kind study, led by Neha Vapiwala, MD, an associate professor in the department of Radiation Oncology at PSOM and Penn's Abramson Cancer Center, found that general quality of life and measurements of side effects often experienced by prostate cancer patients--including fatigue, sexual health, and urinary incontinence--were stable throughout a course of outpatient radiation therapy among the men participating in an intensive yoga program.\nCurrently, the team is randomizing prostate cancer patients to participation vs. no participation in this structured yoga program in order to further characterize the potential benefits of yoga in this population.\nThe possible explanation for the benefits of yoga seen in the study stems from physiologic data demonstrating its ability to help reduce cancer- as well as treatment- related fatigue and to strengthen pelvic floor muscles and increase blood flow.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release does not mention any other interventions that might mitigate the side effects associated with prostate cancer treatment.\nWhile the release mentions other services available at the cancer center \u2014 stress reduction techniques, meditation, reiki therapy \u2014 they are not presented in the context of alternatives for improving quality of life for prostate cancer patients and do seem more in line with marketing the cancer center.", "answer": 0}, {"article": "\"All drugs of abuse operate using some shared pathways.\nThe details of the medical cannabis laws were found to have a significant impact on opioid prescription patterns, the researchers found.\nThe studies, published Monday in the journal JAMA Internal Medicine , compared opioid prescription patterns in states that have enacted medical cannabis laws with those that have not.\nThe impact of these laws also differed based on the class of opioid prescribed.\nBut unlike opioids, marijuana has little addiction potential, and virtually no deaths from marijuana overdose have been reported in the United States, according to Bradford.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article did not mention any other policies being studied for reducing opioid prescriptions, overdoses or deaths.", "answer": 0}, {"article": "Specifically, more than 40 percent of people who were cancer-free said they\u2019d been taking NSAIDs at least once per week for more than 5 years, versus only 28 percent of those who developed melanoma.\nAs a result, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study, Asgari noted.\n\u201cI think it\u2019s just too early\u201d to say NSAIDs offer any protection, she said.\nFor one, you have to get the comparison right, she noted; there\u2019s always a concern that people without cancer who agree to participate in the study may be more health conscious to begin with, and it\u2019s this that protects them from cancer, not their use of NSAIDs.\n\u201cI think the jury is still out.\u201d\n\nThere\u2019s reason to hope NSAIDs might offer some protection against this type of cancer, however - earlier this year, a review found that people who use painkillers such as ibuprofen on a regular basis may be less likely to get bladder cancer.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "It\u2019s curious that the story never mentioned that the study also looked at statins and found \u201cno significant protective effect was observed with statin exposure.\u201d\u00a0 Why wasn\u2019t that mentioned? Negative findings deserve publicity as well.", "answer": 0}, {"article": "Newswise \u2014 Columbus, OH.\nEarly results, which were presented at the Wound Healing Society\u2019s Annual Meeting in April 2016 indicate that infected wounds covered by the experimental bioelectric dressing healed better and more quickly than those covered with a plain dressing that is commonly used in the care of wounds today.\nThe team\u2019s next move is to focus on the bioelectric bandage as a treatment for chronic wounds in a patient population; however, the technology could also be used to treat acute injuries.\nIt could be applied immediately to wounds help keep bacteria from mobilizing and start promoting healing until the soldier could be transported to a facility for more intensive medical care.\u201d\n\nThe team already has interest from several industry partners, and is hoping to begin testing the new technology in patients before the end of the year to determine optimal treatment duration and more about the healing effects of electrical fields on skin cells on a molecular level.\nThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release compares the new technology to plain dressings but without comparative data. It states, \u201cEarly results, which were presented at the Wound Healing Society\u2019s Annual Meeting in April 2016 indicate that infected wounds covered by the experimental bioelectric dressing healed better and more quickly than those covered with a plain dressing that is commonly used in the care of wounds today.\u201d\nIt might have been more meaningful to compare this new WED against existing WEDs.", "answer": 1}, {"article": "Using a technique invented by Brigham & Women's Hospital researchers Piero Anversa, MD, and colleagues, heart stem cells are taken from the tissue and grown in the lab.\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\nThese adult stem cells already are committed to becoming heart cells, but they can transform into any of the three different kinds of heart tissues.\nStudy researcher John H. Loughran, MD, of the University of Louisville, Ky., could barely contain his excitement in an interview with WebMD.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The experimental approach is not compared to existing alternatives. There is \n\n\n\na passing reference to \u201clifestyle changes and medical management\u201d. Were all of these patients taking the same medications and following the same diet and exercise routines prior to the study and during the study? What is currently the best course for the types of heart conditions these patients have? These are among the many questions not answered in the story.\n", "answer": 0}, {"article": "\u201cWhen the drug company sends someone in to give them a talk and buy them pizza, they think they\u2019re getting a scientific lecture,\u201d he said.\nBut each shot costs as much as $1,000, and because the drug has a limited track record, experts do not agree on how well it works.\nA year after treatment stopped, there had been no overdoses in the Vivitrol group and seven overdoses, including three deaths, in the other group.\nDr. Joshua Lee, of New York University\u2019s medical school, said more evidence is needed to determine whether the medication can help substantial numbers of people and whether it\u2019s worth paying for, but the early results are encouraging.\nThe evidence for giving Vivitrol to inmates is thin but promising.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Existing alternatives, such as methodone and buprenorphine, are mentioned and their debits highlighted, but more could have been said about their track record.", "answer": 1}, {"article": "The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery\u00ae brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues\n\nThe American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world.\n\"While we can operate on ears later in the patient's life, waiting not only increases the surgery's difficulty and expense, but may expose the child to teasing, bullying, and loss of self-esteem,\" comments Editor-in-Chief Rod J. Rohrich, MD, in a featured video on the Plastic and Reconstructive Surgery website.\nDr. Byrd comments, \"The EarWell system is effective in eliminating or reducing the need for surgery in all but the most severe congenital ear malformations.\"\nWhile the EarWell system is not new, the report is the largest study of congenital ear malformations treated with this approach--including a standardized approach to treatment and assessment of the results.\nThey also point out that EarWell is highly successful in the treatment of prominent ears--a condition that commonly goes unnoticed by parents and pediatricians, but is likely to get worse as the child grows.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release cites an independent source, stating \u201cWhile we can operate on ears later in the patient\u2019s life, waiting not only increases the surgery\u2019s difficulty and expense, but may expose the child to teasing, bullying, and loss of self-esteem.\u201d We\u2019re giving the benefit of the doubt here since the release suggests delayed surgery as an alternative treatment. It would have been better if the release had mentioned no treatment \u2014 or watch and wait to see if less severe ear deformities resolved on their own \u2014 as an option as well.", "answer": 1}, {"article": "I suspect it's part of the picture, along with lack of exercise and dietary indiscretion.\"\nIf sleep extension could have a salutary effect on helping people lose weight,\" he says, we'd have another tool in the fight against obesity.\nIf your teen has to get up at, say, 6:30 to be at school by 7:30, that means bedtime's at 9:15 or 9:30 p.m.)\n\nVorona says he'd like to delve deeper into the sleep-obesity question.\nRobert Vorona, a sleep researcher at Eastern Virginia Medical School in Norfolk, says adults should aim for 7 to 7 1/2 hours a night, while teenagers need a whopping 9 to 9 1/4 hours.\nInstead, choose whole-wheat crackers, which can control insulin.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There are no data presented on sleep extension and related approaches as\u00a0interventions for weight loss. Thus it\u2019s impossible to compare them to other interventions for weight loss. However, we give it a strike for one reason.\nThe story attempts to put sleep into some kind of context in the overall mechanism of obesity by ending on the sleep researcher\u2019s caveat that he doesn\u2019t believe sleep deprivation is the root cause of the obesity epidemic. But he suspects it\u2019s \"part of the picture, along with lack of exercise and dietary indiscretion.\" The story cites no evidence or study to support his suspicion. We have no idea\u00a0how big or how small a part sleep makes up in that picture. No doubt, Vorona doesn\u2019t know either. But he is still suggesting that sleep deprivation has a role in obesity. The vague point, without evidence or relative qualification, will for some readers\u00a0elevate the role of sleep deprivation relative to the other contributing factors.\u00a0\nIt\u2019s relevant because each factor is associated with a weight loss intervention, and diet and exercise interventions have a warehouse of studies behind them. A brief discussion about the roles of calorie restriction and exercise for long-term weight loss and maintenance would have put the role of sleep interventions in perspective for readers.", "answer": 0}, {"article": "The Site is down for maintenance.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was no comparison made between work on this drug and any other research in this active field of research.", "answer": 0}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not provide any context for the research, in terms of other habits that are known to reduce cardiovascular risk. These include: regular exercise, healthy eating habits and maintaining a healthy weight \u2013 among others.", "answer": 0}, {"article": "Patients taking briakinumab had more serious infections and more cancers than those taking methotrexate.\n\"Many of us were disappointed it was withdrawn because there would be a subset of patients who wouldn't respond to anything else and it would have been nice to have for them.\"\nGordon was not involved in the current study, but he has been involved in research of the drug and has been a paid consultant and investigator for Abbott.\nThe study is published in the New England Journal of Medicine.\nBut as successful as the drug appears to be for some patients, it may come with a significant risk.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "While mentioning the similar drug Stelara, the story didn\u2019t wrap the new research into the context of other approaches to psoriasis \u2013 including some non-drug therapies.\u00a0 It would take only another sentence to give some broader context about other therapeutic approaches.", "answer": 0}, {"article": "; Menno V. Huisman, M.D., Ph.D.; Pieter W. Kamphuisen, M.D., Ph.D.; J\u00f6rg Kreuzer, M.D.\nResearchers say before idarucizumab was available, patients on dabigatran who needed emergency surgery were given purified clotting factors, which carry the risk of patients' clotting systems forming dangerous blood clots.\nThe new results are part of a large on-going phase III study testing idarucizumab in a range of patients who take dabigatran and have dangerous bleeding or need urgent surgery or other procedures that carry serious bleeding risks.\nAn interim analysis of the first 90 patients in a study called RE-VERSE AD (REVERSal Effects of idarucizumab in patients on Active Dabigatran) showed that idarucizumab effectively reversed dabigatran's anticoagulant effects, said Richard A. Bernstein, M.D., Ph.D., lead study author and director of the stroke program at Northwestern Memorial Hospital in Chicago, Illinois.\n\"I see the biggest impact of idarucizumab as providing reassurance to patients that if bleeding while taking dabigatran does occur, we can quickly reverse the dabigatran.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release doesn\u2019t name the three oral anticoagulants that are available including warfarin, which is the power player in this area. Warfarin (brand name Coumadin) is the main alternative and many prefer it to other anticoagulants in spite of the need to check international normalised ratio (INR) levels, which give an indication of clotting risk. That is why this new drug might be important and why the cost comparison we mentioned above is also important.\nInstead of talking about those other important alternatives the release notes that \u201cResearchers say before idarucizumab was available, patients on dabigatran who needed emergency surgery were given purified clotting factors, which carry the risk of patients\u2019 clotting systems forming dangerous blood clots.\u201d", "answer": 0}, {"article": "Imaging equipment makers such as GE Healthcare, Siemens, Philips and Toshiba Medical Systems are working to develop low-dose CT scanners.\nBut CT scans involve much higher radiation dose than conventional X-rays.\nThe findings, published in the Archives of Internal Medicine, add to mounting evidence that Americans are overexposed to radiation from diagnostic tests, especially from a specialized kind of X-ray called a computed tomography, or CT, scan.\nThe researchers said efforts need to be taken to minimize CT radiation exposure, including reducing the number of unnecessary tests, cutting the dose per study, and standardizing the doses across facilities.\nRedberg, who wrote a commentary on the studies, said U.S. doctors\u2019 enthusiasm for the tests has led to an explosion in their use that is putting patients at risk.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not compare CT scanning to any alternatives,\u00a0such as\u00a0other types of imaging tests (MRI scans, ultrasounds, conventional X-rays, etc). Although it is implied, the story should have explicitly mentioned \"no scanning\" as an alternative.", "answer": 0}, {"article": "For tips and recipes, visit LoveOneToday.com or follow HAB on Facebook, Twitter, Pinterest and YouTube.\nResearchers found avocado consumption (1 to 1.5 per day) significantly reduced total cholesterol (TC), \"bad\" low density lipoprotein cholesterol (LDL-C) and triglycerides (TG) when they were substituted for sources of saturated fat.\n\"Fresh avocado, as part of a balanced diet, and as a cholesterol-free substitute for solid fats, can help be part of the solution for maintaining normal cholesterol levels,\" says Nikki Ford, PhD, Director of Nutrition, Hass Avocado Board.\n\"Beyond their naturally good fats, avocados are also a delicious way to boost fiber (8 percent of DV) and fruit intakes, both of which are under consumed in American diets.\"\nThe research, \"Impact of avocado-enriched diets on plasma lipoproteins: A meta-analysis,\" conducted at the University of the Pacific and independently funded , looked at 10 unique avocado studies with 229 participants, assessing the impact of avocados on cholesterol levels.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The beneficial cholesterol-lowering ingredient in avocados is monounsaturated fatty acid (MUFA) which can be found in other foods. The news release doesn\u2019t mention these alternate food sources for MUFA but the study did. It states:\n\u201cSpecific types of nuts are also a good source of MUFA. In a pooled analysis of 25 studies that looked at a variety of nuts (almonds, walnuts, pistachios, peanuts, and macadamias), a mean LDL-C reduction of 7.4% was evident.\u201d", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The news story mentions common treatment options for sciatica, but says little about options other than surgery for degenerative spondylolisthesis (DS). In the new DS study, these included epidural injections and physical therapy.", "answer": 0}, {"article": "After first taking in \u201craw data\u201d of an image through the eye, different sets of neurons in the brain process it as separate features like edges and colors.\nVarious smartphone apps say they offer this kind of vision-improving training; I used one called GlassesOff, the only one I found that was backed by scientific studies.\nHowever, other studies with no commercial links obtained similar results, and several scientists I spoke to, including those without ties to GlassesOff, thought the science behind the app was credible.\nFor example, a study tested the approach in 23 young adults, around age 24.\nIt should be acknowledged that some researchers involved in many of these studies have financial ties to GlassesOff.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story raises the alternatives of bifocals and transitional lenses. It would have been stronger if it had mentioned other alternatives to the app-based brain training, such as simple magnifiers, brighter light, and multifocal lenses now available for those who need\u00a0cataract surgery.", "answer": 1}, {"article": "For more information on asthma, visit the U.S. National Library of Medicine.\nHowever, the study authors and an outside expert stressed that these are early findings and much longer, larger clinical trials are needed.\nFor the study, Peters' team tried three drug regimens on 210 asthmatics.\nIn addition, the combination of an inhaled steroid and Spiriva was not less effective than using an inhaled steroid plus Serevent, they said.\nThe results need to be confirmed in a much larger pool of patients, Peters said, and he noted that the patients were not followed long enough to see if Spiriva was able to reduce the severity of asthma attacks and hospitalizations.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "By the nature of the study, an unapproved therapy was compared to existing alternatives.\u00a0", "answer": 1}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does a good job discussing the different methods of treatment for stroke, and the disparity in the results seen in various studies.", "answer": 1}, {"article": "\"It remains to be seen which method is better.\"\n\"This procedure is gaining ground worldwide as an optional fertility treatment for fertile female cancer patients who after cancer treatment most likely will be infertile,\" said lead researcher Dr. Annette Jensen, from the Laboratory of Reproductive Biology at Rigshospitalet in Copenhagen.\n\"The pregnancy rate with frozen embryos is close to 50 percent, and results are getting better,\" he said, referring to another option for women hoping for a future pregnancy.\nOf 32 women who had ovarian tissue frozen and transplanted in this study, 10 women -- or 31 percent -- had a child, she said.\nThis new study shows that ovarian tissue transplants are safe and effective and pose little risk of the cancer coming back, the Danish researchers said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that instead of the removal of the entire ovary and storage, it is possible patients could choose embryo cryopreservation/freezing. A physician is quoted as follows:\n\u201cThe pregnancy rate with frozen embryos is close to 50 percent, and results are getting better,\u201d he said, referring to another option for women hoping for a future pregnancy. \u201cIt remains to be seen which method is better.\u201d\nWe\u2019d add that embryo cryopreservation/ freezing requires a woman to have a partner or use donor sperm\u00a0AND to undergo IVF \u2014 a lot to do\u00a0in the context of cancer treatment. Freezing unfertilized eggs is another approach where there\u2019s the option to attempt to fertilize them later.", "answer": 1}, {"article": "The women ranged in age from 18 to 86.\nBut previous studies suggest more than 50 percent of these biopsies are unnecessary and can result in pain, worry, infertility and higher health care costs.\nThe new urine test, they say, is different because it analyzes not only multiple sources of human cellular DNA altered by precancerous changes, but also DNA from HPV that is sexually transmitted and causes virtually all cases of the disease.\n\"When developing a new cancer screening test, we want something in the range of 90 to 95 percent sensitivity, which is competitive with the effectiveness of tests developed and now marketed in Europe,\" says Guerrero-Preston.\nTwo commercial tests based on markers of DNA chemical changes called methylation, released in Europe last summer, require Pap smears or swabs of cervical tissue, and show 64 percent sensitivity in identifying similar lesions, according to senior investigator Rafael Guerrero-Preston, Dr.P.H., M.P.H., assistant professor of otolaryngology-head and neck surgery at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The text does a good job of comparing this potential urine test\u00a0to the traditional Pap smear and to two relatively new commercial tests based on a search for methylation in DNA.\nFrom the data provided, this new test offers no advantages in developed countries where Pap/HPV rates are high and follow-up with colposcopy is available. The issues in developing countries are two-fold. One is whether a urine test could be used as an alternative to the Pap smear/HPV test as the first screen. A urine test would be a much easier screening test. But what they\u2019re examining is when the Pap/HPV is abnormal, can you can eliminate the need for some colposcopies.", "answer": 1}, {"article": "This test will most definitely save lives.\"\nPreviously, the only tests for breast cancer risk were for relatively rare genes, leaving most women with no way to assess their individual genetic predisposition.\nWomen with a strong family history can get tested for two genes that sharply increase their predisposition, but they account for only 1 to 3 percent of all breast cancers.\nDoctors can estimate a woman's chances of developing breast cancer based on a variety of factors, including her age and family history, but most women have no way of knowing their precise risk.\nWhile welcomed by some patient advocates and doctors, the $1,625 test raises concerns among others.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story mentions current prevention guidelines for women who are considered at higher than average risk of developing breast cancer. This includes additional surveillance with MRI and mammography, chemoprevention and adopting a healthier lifestyle, namely reducing alcohol consumption and lowering body fat.\u00a0 However, the evidence of survival benefit for lifestyle and screening is fairly limited. Most of recent decrease in breast cancer \u00a0mortality is attributed to advances in treatment not necessarily screening.\u00a0 \nCurrently, breast cancer risk for women who do not carry the BRAC1/2 genes is determined via population-based calculators such as the Gail Risk Model.\u00a0 This tool provides an estimated 5-year risk and is only validated for Caucasian women, so a well-validated, individualized predictive test would, in theory, be useful for some women.\u00a0 The test discussed in this story has not been studied long enough, nor have results of company studies been subjected to an external review. ", "answer": 1}, {"article": "With insurance, copays would be less, he added.\nThere are a couple of reasons for severe hot flashes after breast cancer.\nFor example, the drugs may raise the risk for problems with short-term memory, reasoning and confusion, and may also hike the risk for dementia among older patients, studies indicate.\nChemotherapy may induce early menopause, and drugs that reduce estrogen levels may make hot flashes worse, the research team noted.\nThe U.S. National Cancer Institute has more about hot flashes and cancer survivors.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article makes it sound like the only option for treating hot flashes is menopausal hormone therapy. But, in fact, there are other ways to treat hot flashes that are currently recommended. These include drugs used for other purposes as well as non-drug options like mind-body approaches.", "answer": 0}, {"article": "The Society works closely with many other sports medicine specialists, including athletic trainers, physical therapists, family physicians, and others to improve the identification, prevention, treatment, and rehabilitation of sports injuries.\nNewswise \u2014 COLORADO SPRINGS, CO \u2013 Shoulder instability is most common in the young, athletic population, bringing a focus to how these injuries are best treated.\nThe study examined 121 patients at an average of 51 months post-surgery.\nThe average age of patients was 19 years old.\n\u201cWhile young athletes and parents may be wary of surgery, our study shows the advantages of this treatment approach,\u201d commented Marshall.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release refers to \u201cnon-operative\u201d interventions, but does not say what they are.", "answer": 0}, {"article": "Nov. 24, 2016.\nWe don\u2019t yet understand why patients with TP53 mutations consistently respond to decitabine, and more work is needed to understand that phenomenon.\u201d\n\nResponses to decitabine are usually short-lived, however, with remissions typically lasting for about a year.\nBut new research indicates that such patients, paradoxically, may live longer if they receive a milder chemotherapy drug.\nSome people live a year or two and with a good quality of life, because the chemotherapy is not too toxic.\u201d\n\nRoughly 10 percent of AML patients carry TP53 mutations in their leukemia cells.\n\u201cWith standard aggressive chemotherapy, we only see about 20 to 30 percent of these patients achieving remission, which is the critical first step to have a chance to cure patients with additional therapies.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While the alternative drugs used in chemotherapy are not mentioned by name, they are referred to as the standard therapy. Because it is already known that TP53 patients have a worse prognosis than other patients with the conventional drugs, it appears that therapy with this milder drug shows better outcomes.", "answer": 1}, {"article": "Editor's note: Tune in as Dr. Sanjay Gupta explores the signs, tests and lifestyle changes that could make cardiac problems a thing of the past on \"The Last Heart Attack,\" Saturday, August 27, 8 and 11 p.m.\nThe 351 participants in the study suffered from high cholesterol but were not on a cholesterol-lowering statin medication.\nThe study was published Tuesday in the Journal of the American Medical Association.\nJenkins said participants achieved these results even though compliance to the whole grain, vegetarian diet was only about 40%.\nLead author Dr. David Jenkins, Canada research chair in nutrition and metabolism at the University of Toronto and St. Michael's Hospital, had previously shown the effectiveness of a cholesterol-lowering diet when all the meals were provided to participants.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not clearly explain that the control group in this study was eating the \u201cstandard\u201d diet recommended to reduce risk of heart disease \u2014 an important detail. It also does not discuss how the results compare with those of statin drugs.", "answer": 0}, {"article": "Presenting at the meeting, Shraddha Sapkota, a graduate student in neuroscience at University of Alberta, and her colleagues described how they carefully analyzed the saliva of a group of volunteers participating in an aging study.\nSome had been diagnosed with Alzheimer\u2019s and some with MCI, while others did not have any neurological conditions.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nExperts now believe that the biological processes behind the neurodegenerative condition begin years, if not decades, before memory problems and confusion become noticeable.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "This story focuses solely on research suggesting that a simple saliva test might one day gauge the risk of developing the disease. It doesn\u2019t discuss how\u00a0Alzheimer\u2019s is currently diagnosed or what risk factors might increase one\u2019s likelihood of developing the disease.", "answer": 0}, {"article": "Restless leg syndrome (RLS) is a neurologic disorder causing unpleasant sensations and an urge to move the legs when at rest.\nDisclosures: Dr Kuhn worked without compensation through Lake Erie Research Institute (LERI) during the 5 years of the study of the device and is now receiving compensation for that work.\nResearchers indicate that the pressure produced by the device may also stimulate a dopamine release, similar to massage therapy or acupressure.\nPilot study published in the Journal of the American Osteopathic Association finds targeted pressure device significantly increased sleep for those with moderate to severe symptoms\n\nAuthors from Lake Erie Research Institute in Pennsylvania report an adjustable foot wrap caused to treat restless legs syndrome (RLS) is 1.4 times more effective than the standard pharmaceutical treatment.\nThe RLS device was designed to put adjustable targeted pressure on two muscles in the foot known to relax symptoms of RLS, the abductor hallucis and the flexor hallucis brevis.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "While at first glance it appears that the trial and the release are a comparison with the existing alternative of drug treatment, the release makes no reference to lifestyle changes, massage, hot or cold packs, hot baths, compression sleeves or an FDA-approved vibrating pad (brand name Relaxis), which has gone through far more extensive testing than this foot wrap. Since the main point of the release is to promote an alternative to drug treatment of RLS, failing to mention the FDA-approved vibration device is a serious omission.", "answer": 0}, {"article": "Pulse pressure is the difference between systolic and diastolic (bottom number) in blood pressure readings.\nThe researchers conclude that mangos may be a heart-healthy fruit that may help play a role in reducing the risk of cardiovascular disease.\n\"This is the first study to demonstrate positive vascular effects of mango intake in humans,\" said lead researcher Robert Hackman, with the UC Davis Department of Nutrition.\nBOSTON (June 11, 2018) -- A new study conducted at the University of California, Davis found that two cups of mangos a day had beneficial effects on systolic blood pressure among healthy postmenopausal women.\nMangos contain a mix of polyphenols, including mangiferin, quercetin, gallotannins, and gallic acid, that have been the focus of previous investigations exploring the potential health-protecting properties of mangos.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "There are a host of options for patients who would like to lower their blood pressure \u2014 including a number of pharmaceutical interventions for patients who have high blood pressure. This study focused on healthy adults, so the pharmaceutical interventions are likely not relevant. But there are also a host of lifestyle-oriented options for people who are at risk of high blood pressure or who want to ensure they maintain a healthy blood pressure. These choices include things like reducing sodium intake, being physically active, and maintaining a healthy body weight. None of these things are mentioned in the release. It would have been good to see a reference to incorporating mango consumption into a broader effort involving a healthy diet and lifestyle choices \u2014 rather than treating mango consumption as a stand-alone intervention.", "answer": 0}, {"article": "Swaminath noted that one study published in 2012 found that \"colonoscopy reduced the risk of death from colon cancer by 53 percent, by removing polyps.\nHe believes that the scoring system \"was only modestly able to separate people within the risk groups.\"\nFor now, he said, the data from this study is not strong enough to spur any changes in current screening recommendations.\nThe study found that patients classified under the scoring system as low-risk did, in fact, have far fewer advanced abnormal growths that might develop into cancer, compared to patients classified as high-risk.\nOne expert said more efforts are needed to get people to undergo colonoscopy, which is currently recommended once every 10 years beginning at age 50.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story notes that a variety of screening tests exist, but the relevant alternative here is actually other risk calculators, which the authors of the study\u00a0describe and cite but are not routinely used. The story doesn\u2019t mention these other calculators and why they are seldom used \u2014 context that would have deepened reader understanding of the issue.", "answer": 0}, {"article": "As we cut calories and lose weight, our resting metabolic rate eventually slows and our bodies become less efficient at shedding mass in a process known as adaptive thermogenesis.\nAnd while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\n\"At that point we see almost zero weight loss,\" she explains of her own research.\nHowever, it\u2019s important not to think of them as cheat days.\nBut, Varady believes it\u2019s probably safe to enjoy a slice of cake or bowl of ice cream during the break.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story really could have used a sentence or two at least about published outcomes of other diet schemes to put this new one in context. The only hint of it is from the outside researcher who said her own study of intermittent fasting saw weight loss plateau around 16 weeks.", "answer": 0}, {"article": "About Milken Institute School of Public Health at the George Washington University: Established in July 1997 as the School of Public Health and Health Services, Milken Institute School of Public Health is the only school of public health in the nation's capital.\nVery little help is provided to pregnant smokers who want to quit so the study's findings are important, especially if the strategy can be adjusted to be more effective, Abroms says.\nAdditional studies must be done to find out if Quit4baby can be paired with other smoking cessation tools in order to provide long-term help for pregnant women who want to kick their smoking habit for good, she says.\nThe more intensive intervention did seem to help two subgroups quit smoking at least in the short run, Abroms says.\nThe messages help educate the women about the health risks associated with smoking and they are interactive--allowing a woman to text back for more help if she is experiencing a craving or goes back to smoking.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The text makes the point that there\u2019s scarce assistance for quitting smoking for pregnant women since some stop-smoking aids carry additional risks. But we think the release should have mentioned some of those alternatives that do exist \u2014 quitting cold turkey, gradual quitting, nicotine replacement, medications like bupropion, and counseling. Options that include medications should include consultation with one\u2019s doctor to weigh the risks and benefits of using smoking cessation aids during pregnancy.", "answer": 0}, {"article": "Bushra Imtiaz, Heidi Taipale, Antti Tanskanen, Miia Tiihonen, Miia Kivipelto, Anna-Mari Heikkinen, Jari Tiihonen, Hilkka Soininen, Sirpa Hartikainen, Anna-Maija Tolppanen.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\nHormonal therapy may protect cognition if started at the onset of menopause\n\nIn the present study, long-term use of hormonal replacement therapy was associated with a better performance in certain cognitive domains - global cognition and episodic memory - and a lower risk of Alzheimer's disease.\n\"The protective effect of hormone therapy may depend on its timing: it may have cognitive benefits if initiated at the time of menopause when neurons are still healthy and responsive,\" says Bushra Imtiaz, MD, MPH, who presented the results in her doctoral thesis.\nThe newest results were published recently in Neurology and Maturitas and the earlier results in the Journal of Alzheimer's disease.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The release does not discuss any alternatives. Numerous other other observational studies, many stronger than this one, are exploring possible Alzheimer\u2019s risk reduction strategies involving diet, exercise and \u201cbrain games.\u201d But according to the National Institute on Aging, \u201cSo far, studies have not demonstrated that, over the long term, health or lifestyle factors can prevent or slow Alzheimer\u2019s disease or age-related cognitive decline. Similarly, clinical trial results do not support the use of any particular medication or dietary supplement to prevent these conditions.\u201d", "answer": 0}, {"article": "Sept. 26, 2017.\nNow, a new study led by Washington University School of Medicine in St. Louis shows that dosing warfarin (Coumadin and others) is safer -- producing fewer adverse events such as hemorrhage -- when key elements of a patient's genetic makeup are considered.\nDespite its longtime use, warfarin remains tricky to dose because a person's genetic makeup influences how the drug is processed in the body.\nCompared with patients receiving traditional warfarin dosing, patients dosed with the genetic approach had a 27 percent reduction in adverse events, which was statistically different.\nBut we continue to prescribe it because it is highly effective, reversible and inexpensive.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Although the release briefly mentions the availability of a \u201cnewer anticoagulant,\u201d it should have included a sentence or two about these newer injectable drugs and their overall risks and benefits in comparison to warfarin. It would also have been helpful to tell readers whether the genetic testing that appears to play a role in safer warfarin dosing would have clinical relevance for informing the use of the new blood thinners as well.\nThe fact is that genetic testing is irrelevant for the newer anti-coagulants because they operate in a completely different manner. But all the blood thinners \u2014 old and new \u2014 carry the same risk of bleeding. The problem with warfarin is the variability in blood levels which requires frequent monitoring, hence the genetic tests to guide dosing.", "answer": 0}, {"article": "Packaged in powder form and mixed with liquid, alginate expands in the stomach to form a thick gel, mimicking the effect of a large meal.\nBut that was only the case among people who stuck with the diet study over a few months.\nAnd just feeling less hungry due to a supplement won\u2019t make you lose weight unless you eat fewer calories, said Mattes, who was not involved in the new study.\nNeither the researchers nor the participants knew who was receiving the seaweed supplement.\nJust looking at the effect of the supplement on people who finished the treatment can bias the findings, she said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "There was an important reminder that \u201cjust feeling less hungry due to a supplement won\u2019t make you lose weight unless you eat fewer calories.\u201d The story could have mentioned other evidence-based weight loss approaches including behavioral weight loss counseling.", "answer": 1}, {"article": "An analysis of 106 randomized trials involving more than 250,000 patients examined the effects of newer angiotensin receptor blockers (ARBs) and older angiotensin-converting enzyme (ACE) inhibitors.\nMONDAY, Jan. 4, 2016 (HealthDay News) -- Newer blood pressure drugs are as safe and effective as older medications, new research suggests.\nScientists at the NYU Langone Medical Center in New York City said their findings settle a longstanding debate about which of two types blood-pressure lowering medications studied are better.\n\"This is the first time that we have a clear and consistent message from the three buckets of trials of ACE inhibitors and ARBs, all of which show that there is no outcome difference between the two agents, except for better tolerability of ARBs,\" Bangalore said.\n\"The results of our analysis are especially important for patients, given that many ARBs are now also generic, which reduces their costs,\" he added.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story reports on a study comparing the efficacy of two classes of drugs for treating cardiovascular disease so readers should assume that there are many alternatives on the market.", "answer": 1}, {"article": "The researchers, Drs.\n\"The management of early stage prostate cancer continues to require further randomized controlled studies, which are underway, to determine the true benefit of treatment versus expectant management,\" said Dr. Marc Danziger, an attending urologist at Lenox Hill Hospital in New York City, who was not involved with the study.\nBut the findings are not likely to be practice-changing, said Dr. Richard E. Greenberg, chief of urologic oncology at Fox Chase Cancer Center in Philadelphia, who was not involved with the study.\nWEDNESDAY, May 4, 2011 (HealthDay News) -- Among men under 65 with early stage prostate cancer, those who have the prostate gland removed are less likely to die than those who adopt a \"watchful waiting\" approach, according to a new long-term study out of Europe.\nAlso, the men in this study were diagnosed only after they had symptoms, unlike the majority of men in the United States, Greenberg said.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story included a list of the commonly available treatment options for early stage prostate cancer.\nBut we must give an unsatisfactory score because the story included a factually incorrect statement indicating that watchful waiting is synonymous with active surveillance. \u00a0It is not. \u00a0 The story went on to misinform readers by indicating \u201cwatchful waiting is often recommended when a man is not expected to die of the cancer\u201d by failing to complete the thought by explaining that the reason they are not expected to die of the cancer is because their advanced age makes it unlikely that the cancer will have sufficient time to progress to lethality OR because they have other diseases from which they are likely to succumb before there is time for the prostate cancer to be deadly.", "answer": 1}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nAlthough the studies were small in scale, researchers said the experiment proved that the concept of screening for chemical signals was promising and that the first Alzheimer's blood test might be within reach after further large scale studies.\nWhile much of the scientific work, including that at Stanford, is promising, Goldstein said all the technologies are a long way from being available in clinics.\nDr. Jerome Goldstein, director of the San Francisco Alzheimer's and Dementia Clinic, said there are very few objective tests to diagnose Alzheimer's disease, and most of them are complex and expensive.\nMore intriguing is a test that examined stored blood samples and predicted Alzheimer's disease in 20 of 22 patients who developed the disease 2 to 5 years later.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story\u00a0made reference to\u00a0several other tests which are currently being explored for use in detecting Alzheimer\u2019s disease.\u00a0 While it did mention MRI, the story did not mention current approaches to diagnosis (i.e. eliminating other possible diagnoses).", "answer": 0}, {"article": "Despite a similar number of reported cases of breast cancer among African-American and European-American women, African-Americans experience a more aggressive clinical course and a 40 percent higher death rate than European-Americans among premenopausal and menopausal breast cancer patients.\nThis is the first clinical study to suggest that neoadjuvant chemotherapy (treatment prior to surgery) may improve breast cancer recurrence rates and patterns in African-Americans.\nThe patients' self-reported races were primarily African-American and European-American.\nCo-authors of the study include Jun Xia, Sergey Klimov, Pranay Neema, Dr. Dora Il'yasova, Dr. Padmashree C. G. Rida, Dr. Remus Osan and Dr. Aneja of Georgia State; Dr. Guilherme Cantuaria and Dr. Mildred Jones of the Northside Hospital Cancer Institute; Dr. Uma Krishnamurti, Dr. Xiaoxian (Bill) Li and Dr. Michelle D. Reid of Emory University; and Dr. Meenakshi Gupta of West Georgia Hospitals.\nATLANTA--Administering chemotherapy to African-American breast cancer patients prior to surgery could improve their prognosis and survival rates from the disease, according to a new study.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release discusses the alternative here (surgery first and chemo or other treatments after), and why they so far don\u2019t seem to be as helpful to African American women.", "answer": 1}, {"article": "She enrolled in a trial, and by the third treatment session, \u201cI noticed a dramatic difference,\u201d she said.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\n\u201cIt was receding.\u201d\nBy middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\nNothing worked.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story points out that liposuction is an alternative.", "answer": 1}, {"article": "They rated themselves as healthier and were less likely to report problems with mobility, pain, daily activities, social interactions and feelings of depression and anxiety, among other factors that can compromise well-being.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\n\u201cMost say they wish they\u2019d done it 10 years sooner.\u201d She explained that the overwhelming majority of patients who undergo bariatric surgery have spent many years trying \u2014 and failing \u2014 to lose weight and keep it off.\n\u201cBariatric surgery is probably the most effective intervention we have in health care,\u201d says Laurie K. Twells, a clinical epidemiologist at Memorial University of Newfoundland.\n\u201cI haven\u2019t come across a patient yet who wouldn\u2019t recommend it,\u201d Dr. Twells said in an interview.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story refers to non-surgical weight loss options only obliquely, noting that \u201cthe overwhelming majority of patients who undergo bariatric surgery have spent many years trying \u2014 and failing \u2014 to lose weight and keep it off.\u201d A basic summary of other weight loss options, including lifestyle changes, medical management and pharmaceutical treatments, was needed.", "answer": 0}, {"article": "For adult males, the recommended amount is 90 milligrams per day.\nFor the rest of us, the chances of vitamin C warding off colds is so slight, the lead researcher concludes it \"doesn't make sense to take vitamin C 365 days a year to lessen the chance of catching a cold.\"\nThe message from the researchers, Senay observed, is that, if your activity profile doesn't match that of people like these, vitamin C won't keep colds away.\nCitrus fruits and juices, strawberries and broccoli are among the many foods that are rich in vitamin C.\n\nSo, where does this research leave us in the fight against the common cold?\nShe explained that a review of numerous studies concluded that vitamin C isn't what it's cracked up to be, failing to help prevent the common cold in any meaningful way, except in some people exposed to extremely high stress.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "When the discussion shifts to the importance of adequate intake of vitamin C, the physician-journalist fails to make sufficiently clear that the known benefits of vitamin C are from eating whole foods high in the vitamin.\u00a0Thus the viewer does not fully understand that eating these foods is a wise alternative to taking the supplements. \u00a0\nThe report ends nicely with the note that the only proven method of reducing colds risk is to wash hands. ", "answer": 0}, {"article": "The other three people served as the control group.\nAlthough the treatment didn't wean anyone off insulin completely, average blood sugar levels dropped significantly, which would reduce the risk of long-term complications.\nIf we can control the autoimmunity, we may reverse the diabetes.\nThe researchers have dubbed this \"Stem Cell Educator Therapy,\" because while exposed to the stem cells, the lymphocytes seem to relearn how they should behave.\nAlso, he noted that the study involved only 15 Chinese people, and that type 1 diabetes is a bit different in that population.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does of course mention insulin treatment. However, it tells readers that by reducing blood sugar levels this new treatment would reduce complications from diabetes. This trial did not look at complication rates. Until there is evidence developed about complication rates in patients using this new type of treatment it is impossible to claim it is superior to standard therapy. After all, even if patients use less insulin, that fact alone does not guarantee that they will have better long-term health outcomes.", "answer": 0}, {"article": "MayoClinic: Find out more about melanoma\n\nOne study presented at the American Society of Clinical Oncology's (ASCO) conference on Sunday focused on the experimental drug vemurafenib.\nNearly 90% benefited from this new targeted drug, Schuchter said.\nBut in many cases that are nine or 10 months they otherwise would not have had.\nThis is very unusual in the world of drug development, he said.\nDoctors and researchers will now explore how to best use these drugs -- give one before the other, or simultaneously.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "Adequate job reporting the comparisons seen in the trials of the two drugs.", "answer": 1}, {"article": "As they age, people with elevated diastolic blood pressure are at a higher-than-average risk of developing elevated systolic blood pressure.\nThe findings, published in the Journal of Nutrition today, suggest that whole grains can be a key regulator of blood pressure, and could provide an effective nutritional strategy to reduce cardiovascular-related deaths and disorders.\n\"The uniqueness of this study is that each of the 33 participants consumed both diets,\" said Kirwan.\nThese evidence-based data demonstrate the effect of diet on cardiovascular disease outcomes, particularly diastolic blood pressure.\"\n\"This level of control can only be performed for small numbers and provides the essential empirical data that cannot be obtained from large observational studies.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "Since the study itself is a comparison between diets rich either in whole grains or refined grains, it\u2019s obvious that there are a multitude of diet alternatives.\nAs mentioned above, more details on the contents of the diet would have been beneficial.", "answer": 1}, {"article": ".\nPatients included in the trials were still having flare-ups despite a year of a standard treatment known as \"triple inhaled therapy\" that includes bronchodilators and glucocorticoids.\nMepolizumab is already approved by the Food and Drug Administration (FDA) to reduce symptom flare-ups and improve quality of life in eosinophilic asthma.\nThe 300-milligram dose did not provide an advantage over the lower dose.\nThe new study reports the results from two Phase III clinical trials evaluating the efficacy of mepolizumab, an antibody treatment that reduces the number of eosinophils in the blood, in moderate to severe treatment-resistant eosinophilic COPD by blocking the pro-inflammatory effects of interleukin-5.\n", "question": "Does the news release compare the new approach with existing alternatives?", "explanation": "The news release notes the standard treatments for COPD are \u201ctriple inhaled therapy\u201d including bronchodilators and glucocorticoids.", "answer": 1}, {"article": "For example, the U.S. Preventive Services Task Force, a federal expert panel, currently doesn\u2019t recommend routine cholesterol screening in any children.\n\u201cUnfortunately, there is no evidence that starting a ten-year-old on cholesterol-lowering drugs will prevent heart disease 40 years later,\u201d said Dr. Michael L. LeFevre, a member of the task force.\nHe said statin treatment in children was still controversial, and that no long-term safety data existed.\nIn a report published in the journal Pediatrics, they call for screening of all children, expanding one set of current recommendations that target only those whose parents or grandparents have heart disease or high cholesterol.\n\u201cIt is therefore prudent to implement universal screening in the pediatric population independent of family history,\u201d the researchers conclude.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story includes an expert who argues against universal cholesterol screening for children. It also points out that lifestyle changes would be part of the treatment considered for children who have elevated cholesterol.", "answer": 1}, {"article": "The surgery \u201chad a transforming effect on how they get along in life,\u201d Dr. Tripathi said.\nNot only \u201cdoes it reassure us that several surgical procedures are effective,\u201d she said, it demonstrates that surgery \u201cshould be done as early as possible\u201d once it becomes clear that a child is not responding to two anti-seizure medications.\nRather than pay $35,000 to $50,000 on surgery that might cure the problem and prevent further damage to the child, insurance companies prefer to demand that more drugs be tried, even if the odds of them working in drug-resistant cases is small, he said.\n\u201cThe study in kids shows if you reduce the time from the onset of seizures from the 15 to 20 years you see in adults down to four to five years, the outcome is much better.\nThe researchers said that was to be expected and, without surgery, patients probably would have experienced similar problems as a result of their continuing seizures.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The article does note that drug therapies are standard of care, but does not specify what drugs are used. More significantly, because the article does not specify in any real detail what kinds of surgeries were performed on the study group, it is difficult for readers to compare alternatives.", "answer": 0}, {"article": "\u201cIn the Northern hemisphere, the body\u2019s testosterone production naturally declines from November through April, and then rises steadily through the spring and summer with a peak in October.\u201d\n\nLow sexual desire can affect significant numbers of men after the age of 40, with studies finding that up to 25 percent of men report problems.\nFagiolini\u2019s team recruited 38 men diagnosed with either hypoactive sexual desire disorder or sexual arousal disorder \u2013 both characterized by a lack of interest in sex.\nBut after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\n\u201cBefore treatment, both groups averaged a sexual satisfaction score of around 2 out of 10.\nScientists at the University of Siena in Italy found that regular, early-morning use of a light box \u2013 similar to those used to combat Seasonal Affective Disorder or SAD - helped men increase testosterone and improved their sex lives.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "The story does not compare light therapy with existing treatment options for lack of sexual desire among men, such as antidepressants, testosterone injections and couples therapy.", "answer": 0}, {"article": "Santarelli describes gantenerumab as a drug engineered to bind itself to plaques known as amyloid-betas, which accumulate as Alzheimer's progresses.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nThe study is published in the online edition of Archives of Neurology.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\nWhat is not entirely known at this point, though, is if these plaques cause Alzheimer's or are by-products of the disease.\n", "question": "Does the story compare the new approach with existing alternatives?", "explanation": "We preferred how HealthDay explained:\u00a0 \u201cThere are approximately one dozen therapies, including vaccines, that are currently in the pipeline\u2026.none are ready for prime time.\u201d", "answer": 0}]